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SUMMARY 
The role of bacterial small RNA (sRNA), i.e. RNA species between 50-500bp in size, in 
virulence, pathogenesis and drug resistance is gaining interest.  In some bacterial species, it 
had been shown to play a crucial role in bacterial transcriptional and post-transcriptional 
regulation. sRNAs from various pathogenic bacteria were shown to modulate bacterial 
responses to the host and environment.  In Mycobacterium tuberculosis, the causative agent of 
tuberculosis, more than 1000 sRNA species have been identified already; but the role of these 
sRNA in pathogenesis, virulence and stress responses is not well studied. 
Central dogma suggests that drug resistance in M. tuberculosis is associated with mutations in 
specific genes. However, a number of clinical drug resistant isolates do not harbour mutations 
in these genes, implicating other factors such as unknown mutations, as well as altered 
regulation of these resistance genes. Prediction of resistance, using molecular methods, can 
therefore be inaccurate in cases where known mutations are absent. In cases where known 
drug-resistance associated mutations are absent, mutations in other genes that regulate such 
resistance-associated genes might influence drug resistance. Growing evidence, in other 
bacteria and M. tuberculosis, hints at a role for mutations in intergenic regions and sRNAs 
species to play a role in bacterial growth and drug sensitivity.  In light of this we hypothesised 
that mutations in sequences encoding sRNA or in sRNA target sequences influence the 
phenotype of M. tuberculosis clinical isolates. 
Using previously identified sRNA genes; we screened a genomic bank of clinical M. 
tuberculosis isolates for the presence of mutations in these sRNA encoding genes. A large 
number of isolates showed mutations in genes encoding for sRNAs.  Furthermore, over-
expression of sRNA using the plasmid pMV306 in Mycobacterium smegmatis showed 
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differences in growth indicating that the presence of the extra copies of the three sRNA (mcr3, 
ASpks and mpr6) had a phenotypic effect on the bacterium. Overexpressed sRNAs did not 
affect the bacterial drug resistance phenotypes, although this requires further investigation 
before concluding the effect of sRNAs on drug resistance. We successfully modified a method 
to extract and purify sRNAs from Mycobacterium species, clean enough to perform Real Time 
Polymerase Chain Reaction even with small amounts. However challenges were faced in terms 
of quantification. Another challenge that still remains is obtaining reference genes specifically 
for sRNAs as we currently have none.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
P a g e  | 4 
 
OPSOMMING 
 
Die rol van klein ribonukleïnsure ( m.a.w RNS spesies van ongeveer 50-250bp in grootte) in 
bakteriële virulensie, patogenese en antibiotika weerstandigheid word al hoe meer 
bevraagteken.  'n Rol vir hierdie nukleinsure in transkripsie en post-transkripsie regulering was 
voorheen gewys in verskeie bakteriële studies, waar dit gedemonstreer was dat hierdie RNA 
spesies n rol speel vir die bakterieë om aan te pas in die gasheer se omgewing 1–3.  Meer as 
1000 klein RNS spesies is voorheen in Mycobacterium tuberculosis (die bakterie wat 
tuberkulosis veroorsaak) geïdentifiseer, maar die rol van hierdie RNA in patogenese, virulensie 
en stress reaksies is nie bekend nie.  
Antibiotika weerstandigheid in M. tuberculosis word tans geassosieer met mutasies in 
spesifieke gene.  Daar is wel n aantal weerstandige isolate waar hierdie bekende mutasies 
heeltemal afwesig is, wat suggereer dat ander rolspelers aanleiding kan gee to 
middelweerstandigheid.  Byvoorbeeld, veranderde regulering van transkripsie patrone van 
gene (wat n bekende rol in weerstandigheid het) mag  ook aanleiding gee tot weerstandigheid, 
maar sulke alternatiewe meganismes is nog nie goed ondersoek in die bakterium nie.  Dis 
belangrik om al die rolspelers te identifiseer, want bestaande molekulere diagnostiese tegnieke 
fokus slegs op bekende gene; dus sal weerstandigheid gemis word in isolate waar bekende 
mutasies afwesig is en slegs molekulere tegnieke gebruik word.  Die potensiële assosiasie van 
klein RNS in tuberkulose antibiotika weerstandigheid is voorheen in n paar studies gemaak.   In 
lig van hierdie studies, is dit voorspel dat mutasies in klein RNA kan aanleiding gee tot 
verandering in die sensitiwiteit teenoor antibiotika in M. tuberculosis.   
Vir hierdie studie het ons n genoom bank, wat bestaan uit individuele genome van kliniese 
M.tuberculosis isolate, geanaliseer vir die teenwoordigheid van mutasies in klein RNS. Daar 
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was spesifiek gefokus op die klein RNS spesies wat in vorige studies met antibiotika 
weerstandigheid geassosieer was.  Hierdie bio-informatiese analise het mutasies in klein RNS 
spesies in n groot aantal weerstandige stamme geïdentifiseer.  Hierdie mutasies was nie in 
sensitiewe isolate gevind nie,   Om die rol van spesieke RNS spesies te ondersoek, was 
rekombinante plasmiede geskep wat bestaan het uit  spesifieke klein RNS spesies van M. 
tuberculosis en die plasmied pMV306.  Hierdie rekombinante was getransformeer in 
Mycobacterium smegmatis. Die teenwoordigheid van hierdie M. tuberculosis klein RNS kopieë 
in M.smegmatis het n negatiewe impak gehad op groei, en dui aan dat hierdie RNA spesies, 
naamlik mcr3, ASpks and mpr6, n potensiele belangrike rol het in die fenotipe van 
mikobakterieë het.  Die ekstra kopieë het nie veranderinge veroorsaak in sensitiwiteit van 
M.smegmatis teenoor die antibiotika moksifloksasien en kanamisien nie, hoewel meer studies 
gedoen moet word voordat definitiewe konklusies gemaak kan word. 
In die finale deel van die studie, is n metode ontwerp om  klein RNS op n makliker,vinner 
manier te isoleer van mikobakterieë.  Hierdie metode was suksesvol aangewend om DNA-vry, 
hoë kwaliteit RNS, beide groter RNA en klein RNS spesies te isoleer.  Die klein RNS was 
goeie kwaliteit, DNA-vry en kon omskep word in DNA met retrotranskripsie. Laasgenoemde 
DNA kon ook gebruik word in verder polymerase kettingreaksies. Dit het dus potential vir 
kwantitatiewe studies om die regulering van klein RNS te studeer.  
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CHAPTER 1 
GENERAL INTRODUCTION 
Background, Problem statement, aims and 
hypothesis 
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1.1 BACKGROUND: 
Mycobacterium tuberculosis (hereafter referred to as M. tb) is the causative agent of 
tuberculosis (TB). South Africa has the third-largest TB burden in the world with a reported 
incidence of 948 cases per 100 000 population annually1.  The evolution of drug resistant (DR) 
strains of M. tb is a major hindrance to the treatment and eradication of TB. Not only must new 
drugs be developed as a result of the old ones becoming ineffective, but measures should be 
implemented to ensure more effective use of the existing and the prospective drugs. Treatment 
options and outcomes of DR-TB are not optimised and patients with contagious and highly 
resistant TB (Multi-Drug Resistant - MDR and Extensively Drug resistant - XDR) strains even 
being sent home, mainly because they have exhausted all available treatment options 2,3. These 
therapeutically destitute persons, as well as an overburdened health care system that cannot 
cope with the number of TB patients requiring hospitalisation further  promotes community-
based spread of the disease. 
 DR in M. tb is associated with mutations in specific genes, but more studies to characterise the 
regulation of DR and resistance genes are needed. Current molecular diagnostic methods to 
screen for drug resistance include only known targets. Prediction of resistance with the aid of 
only molecular methods can therefore be misleading in cases where known mutations are 
absent. More studies are therefore needed to investigate other causative bacterial factors such 
as unknown mutations, and/or altered regulation of these resistance genes. Understanding 
regulation of these genes could be a key factor in curbing DR-TB. One aspect of these 
regulatory factors includes gene products such as regulatory proteins and/or small RNA. 
Small RNA (sRNA) species have been described in various pathogenic bacteria and were 
shown to modulate bacterial responses to the host and to the environment 4. Understanding the 
role played by sRNAs in gene regulation could broaden our view of the mechanisms involved 
in TB infection, particularly the poorly understood mechanisms involved in drug resistance and 
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latency. This will also improve diagnosis of drug resistance and the development of new and 
more efficient drug therapies for the disease.  A recent study found significant association 
between the presence of mutations in sRNA genes and intergenic regions with drug resistance 
in M. tb. Although functional studies are lacking, such a significant association suggests that 
these mutations potentially play a role either in drug resistance itself, or the evolution thereof, 
or potentially could aid the survival of multidrug-resistant bacteria where various genes are 
mutated and therefore render functionally impaired products. 
1.2 PROBLEM STATEMENT: 
Knowledge of the all the mechanisms involved in TB drug resistance is lacking, especially in 
isolates that lack known mutations associated with drug resistance. Growing evidence suggests 
a role for mutations in intergenic regions and sRNAs in gene regulation, but more studies are 
needed to understand its role in DR-TB. Binding of a sRNA to a target at post-transcriptional 
level can either promote or hinder translation, possibly of genes associated with drug resistance. 
More studies therefore need to be done to provide an insight into how small RNA influences 
drug metabolisms and phenotype in M. tb.  
1.3 HYPOTHESIS:  
Mutations in genes encoding small RNA affect regulatory pathways that may alter the 
phenotype of M. tb clinical isolates, including their sensitivity to anti-tuberculosis drugs.  
 
1.4 OVERALL AIM: 
 To characterise the role of sRNA in M. tb, with the main focus on their potential role in drug 
resistance. 
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1.5 CLINICAL IMPLICATIONS  
- To broaden our understanding of drug resistance mechanisms in M. tb resulting in the 
improvement of diagnostic methods and the development of more efficient drug 
therapies against tuberculosis. 
 
 
1.6 OBJECTIVES AND EXPERIMENTAL APPROACH   
Objective 1: To establish if single nucleotide polymorphisms (SNPs) occur in sRNA genes in 
clinical isolates with various phenotypes. 
Method:   
i) Literature search and bio-informatics analysis of published sRNAs from M. tb in 
order to select candidates.   
ii) Screening for mutations in candidate sRNAs in the genomes of a large set of 
clinical isolates of different strain lineages. Additionally, whole genome sequences 
from published M. tb genomes will be examined for the presence of SNPs in the 
sRNA genes. 
 
Objective 2: To characterize the expression of sRNAs identified in objective 1 (mcr3 and 
ASpks) after exposure of M. tb to anti-TB drugs (kanamycin, moxifloxacin). 
     Method: 
i) A method to extract sRNAs from mycobacteria, without the use of cumbersome 
agarose gel purification methods, will be devised and optimized using a 
combination of known commercial available kits; the method will be optimized in 
M. smegmatis. 
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ii) Actively growing, log phase cultures of M. tb will be exposed to TB drugs and 
sRNAs will be extracted using the method in (i). 
iii) The levels of specific sRNAs in antibiotic exposed and unexposed samples will be 
compared using quantitative reverse transcription PCR.   
 
Objective 3: To characterise the effect of sRNAs on the phenotype of M. smegmatis.  
Method: 
i) Candidate genes will be cloned and expressed in M. smegmatis, using plasmid 
pMV306, as well as in a plasmid construct with the TET on/off controllable 
promoter. 
ii) Transformants will be characterised using growth curves to assess growth 
phenotype and drug sensitivity tests.  
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CHAPTER 2 
LITERATURE REVIEW 
BACTERIAL SMALL RNAs, THEIR DISCOVERY, ROLE 
AND POTENTIAL USE AGAINST PATHOGENS SUCH AS 
MYCOBACTERIUM TUBERCULOSIS 
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2.1 INTRODUCTION 
Prokaryotes, eukaryotes and viruses all have evolved numerous strategies to control gene 
expression, which allows for increased versatility and adaptability to changes in the 
environment. Gene regulation can occur at the level of DNA transcription, post-translationally 
and post-translationally. Effectors such as small non-coding RNAs (sRNAs) can provide 
additional knowledge on the mechanisms of gene regulation. The discovery of sRNAs as 
effectors of post-transcriptional regulation adds to our understanding of the complex processes 
involved in gene regulation. However, large knowledge gaps still exist regarding the roles of 
sRNAs in bacteria particularly in Mycobacterial species. 
In this review we summarize some of the key strategies employed by bacteria in regulating 
gene expression via sRNA molecules. We detail gene regulation by sRNAs, with an emphasis 
on Mycobacterium tuberculosis (M. tb), the pathogen responsible for the global tuberculosis 
(TB) epidemic. We also explore the possibility that sRNAs can contribute to drug resistance in 
clinically relevant pathogens, such as M. tb, and discuss the potential to use sRNAs or their 
targets in antimicrobial therapy.   
2.2 THE DISCOVERY AND SIGNIFICANCE OF SMALL RNA MOLECULES 
sRNAs range in length from 50 to 500 nucleotides 5. The significance of sRNAs was first 
appreciated in plants, fungi, protozoa and metazoan animals in which they were referred to as 
micro RNA (miRNA) and were shown to function in transcriptional and post-transcriptional 
gene regulation 6–8. miRNA was comprehensively described in 19936, but did not receive 
widespread recognition as a distinct component of gene regulation with conserved functionality  
until the 21st century. 
sRNAs are important regulators because of their small size which translates to a quicker 
response to stimuli. Their small size means they can be rapidly synthesised in large quantities, 
easily locate their targets and are quickly degraded 9. This allows the bacteria to rapidly and 
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efficiently integrate and respond to multiple environmental changes in a chronologically 
efficient way. 
Although discoveries of sRNAs date back to the 1980s, their significance and role as bacterial 
regulatory components were only appreciated more recently. An understanding of how sRNAs 
function in gene regulation provides researchers with knowledge of how bacteria control their 
biology/physiology 10 for instance during oxidative stress, phage development, bacterial 
virulence, developmental control and is also important in understanding drug resistance and 
persistence 11. One of the first significant discoveries of a sRNA in bacteria with regulatory 
activities in bacteria was made in 1981, with the description of an approximately 108 nucleotide 
sRNA linked to the inhibition of ColE1 RNA primer formation by an antisense base pairing 
mechanism of a plasmid-specific RNA 12,13. In 1983 another sRNA, approximately 70 
nucleotides long, was described and linked to inhibition of transposase translation by pairing 
with the transposase mRNA 14. The first chromosomally encoded sRNA, *MicF 
(approximately 174 nucleotides long), was discovered in 1984 in Escherichia coli. It blocks 
translation of a major outer membrane porin OmpF 15. However some of the early sRNAs 
turned out to be proteins commonly referred to as transcription factors and this halted research 
into sRNA.  
The recent rediscovery of sRNAs as regulatory elements has resurrected the interest into 
sRNAs as regulators. Subsequently, many of the already described sRNAs have been found to 
be conserved in closely related bacterial species 16,17. To date, several sRNA molecules have 
been discovered in E. coli and other bacteria 18–25. 
* Small RNAs are not written in italicised format as do genes.  
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2.3 METHODOLOGY TO IDENTIFY SMALL RNAs 
Technical advances offer the potential to comprehensively identify further sRNAs, which will 
advance our understanding of these important molecules. Experimental approaches such as 
direct labelling and sequencing initiated the discovery of sRNAs. An example of direct 
labelling and sequencing involves metabolically labelling total RNA (tRNA) derived from 
bacteria, followed by gel fractionation with P-orthophosphate. Putative sRNAs would be 
visible as small single bands on the gels. This method is advantageous particularly in 
identifying sRNAs that are up-regulated in specific stress conditions (reviewed by Aluvia et 
al) 26.  
Due to their relatively small sizes, sRNAs are difficult to identify by genetic screening and 
other molecular methods. However, given the growing availability of whole genome sequence 
data supported by experimental verification, it is now possible to identify a large number of 
sRNAs that could have been missed by more targeted genetic screening methods alone.  
Various computational prediction methodologies are used to identify sRNAs. Comparative 
genomics, one of the most frequently used methods, involves exploiting the similarities seen 
between genome structures/sequences and using these to find and predict function of new 
sRNAs to a significant accuracy 27. “Orphan” transcriptional signals such as promoters and 
rho-independent terminators found in the intergenic regions are some of the parameters used 
in designing sRNA computational identification tools 28. Some sRNAs are found in multiple 
species, and in some cases their function is conserved. For example, the sRNA MicF exerts 
similar effects on ompF in Yersinia and E.coli, that is, inhibition of translation of the ompF 
mRNA 29. This similarity in function could be exploited to predict sRNA function in different 
bacteria. 
The ab initio method is another widely used computational method which takes advantage of 
the occurrence of similarities in protein/RNA-coding nucleotide sequences termed “signals”. 
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Some of these “signals” include promoter sequences, transcription factor binding sites, specific 
sRNA structures, di/tri-nucleotide preferences, existence of preferred sequences such as GC 
content. RNAGENiE is an example of a tool that uses the ab initio method in which it predicts 
sRNAs by identifying commonly shared structures such as double helices, UNCG tetra loops, 
GNRA tetra loops, tetra loop receptors, uridine turns, adenosine platforms etc. 30,31. Other tools 
include the Glimmer system 32–34 and GeneMark 35–37. The ab initio method is less suited for 
more complex (e.g. eukaryotic) organisms. 
The biogenesis of sRNA transcripts is not well understood. Studies of eukaryotic sRNAs 
(miRNAs) have provided evidence of secondary processing of miRNAs after transcription. 
This includes formation of a primary miRNA (pri-miRNA) which is then cleavage by protein 
assisted enzymes (Microprocessor complexes) into precursor miRNA (pre-miRNA). The pre-
miRNA is transported into the cytoplasm where further cleaving occurs to produce mature, 
functional miRNA 38–41. There is currently no evidence showing similar or related mechanisms 
in bacterial sRNAs. This should be further investigated in order to provide further 
understanding of gene regulation leading to new drug targets and/or non-chemical but rather 
RNA based therapeutics. 
2.4 CLASSIFICATION OF SMALL RNAs 
Small RNA molecules have been associated with regulation of bacterial gene expression both 
at transcript and protein level. Depending on the nature of the molecule being targeted, sRNAs 
can be divided into two broad classes. Those that base pair with their target mRNA, often 
termed base-pairing or antisense RNAs, form sRNA-mRNA complexes that modify translation 
and stability of target mRNA 42. The second class consists of sRNAs that bind and modify the 
function of metabolic proteins 43including regulatory proteins by antagonizing their functions 
44. The base pairing or antisense RNA (asRNA) have been the most and extensively studied 
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group of sRNAs and have been linked to regulatory responses as a result of environmental 
changes. 
The base pairing group of prokaryotic sRNAs can be further grouped into two sub-classes. The 
first of these, cis-encoded sRNA species, are encoded in the same DNA region but on the 
opposite strand to the target DNA coding strand as discrete molecules. They have extensive 
potential to base pair with their target due to full base pair complementarity and they are 
diffusible molecules. The second class, trans-encoded sRNAs are encoded on another 
chromosomal location and are partially complementary to their target mRNAs. Unlike cis-
encoded sRNAs, trans-encoded sRNAs exert their function in “trans” as diffusible molecules 
and can have multiple targets 44,45. These sRNAs have been associated  mostly with negative 
regulation of translation and/or mRNA stability 5. 
Another broad classification categorizes sRNAs according to those that interact with the Sm-
like chaperone protein, Hfq, and those that do not. Sm proteins form part of specific small 
nuclear riboproteins (nnRNPs) involved in the processing of pre-mRNAs to mature 
mRNAs; as a major part of the spliceosome.. The Hfq chaperone molecule forms complexes 
with the A/U-rich regions of sRNAs providing a stable platform for sRNA-mRNA interaction 
46.  
2.4 SMALL RNA-mRNA INTERACTIONS ARE ENHANCED BY NUCLEIC ACID 
BINDING PROTEINS LIKE HFQ 
Prokaryotes have acquired a cascade of RNA binding proteins (RBPs) as part of post-
transcriptional regulation 47. Hfq is one such example, and is an abundant bacterial RNA 
binding protein 48, which is implicated in various crucial regulatory processes. Hfq in E.coli 
was originally shown to regulate its own synthesis by binding to the 5’ UTR region of its own 
mRNA, thereby inhibiting the formation of a translation initiation complex (Figure 1).   This 
protein assists in the antisense interaction of mRNAs and sRNAs by providing a stable platform 
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for the association to occur 46. The Hfq mediated association of the sRNA and the target mRNA 
occurs via two RNA binding sites on Hfq, one site binds sRNA whilst the other site connects 
to the mRNA target. Hfq thus acts as a chaperone that aids the binding of sRNA molecules to 
their target mRNA molecules 49. This property can be exploited to isolate sRNAs from various 
microorganisms, including mycobacteria 50.  
The Hfq chaperone protein is mostly required by trans-encoded sRNAs to stabilise sRNA-
target mRNA complex formation probably because of the short, imperfect base pairing 
interactions with target mRNA associated with these sRNAs 51. The Hfq chaperone proteins 
not only stabilize sRNA-mRNA complexes but also can protect them from degradation 52. 
However in E.coli it was found that Hfq bound to sRNA and its target,  affecting the stability 
of mRNA by interfering with RNase E degradation 53,54. Several research studies have shown 
associations between Hfq and proteins such as Pol(A) polymerase 1 (PAP 1), Poly nucleotide 
phosphorylase (PNP) and RNase E narrowing the possible functions of the sRNAs involved 55–
58. Hfq-dependent sRNA regulation has also been reported in the gram-positive bacterium 
Listeria monocytogenes 59,60.  
Hfq protein has been implicated in the regulation of virulence in gram negative bacteria, such 
as Klebsiella pneumoniae 61,62. It has also been shown to regulate the σ-mediated general stress 
response in E. coli 63. The latter study showed that the Hfq molecule regulates the σ32-mediated 
cytoplasmic heat shock response and secondly that it is fundamental for long-term adaptation 
of σ32 to chronic chaperone overexpression 63. Hfq also acts as a host factor required for Ԛβ 
phage replication 48,64(involves the Ԛβ replicase complex used by viruses to hijack host 
translation elongation factors in order for it to multiply65). 
It has been suggested that sRNAs are important role-players in stress-induced adaptive 
responses and are therefore a key part of bacterial pathogenesis 66.  A complete understanding 
of how sRNAs function as regulators of gene expression is lacking, although a few studies have 
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characterized sRNA candidates in terms of their target and effect. These studies have shown 
that the majority of sRNAs are antisense RNAs that function through base pairing 
mechanisms67. The most studied sRNAs, the “trans-encoded” sRNAs, are transcribed from 
intergenic regions of DNA, and pair with imperfect complementarity to their targets. As such 
these sRNAs are sometimes associated with having multiple targets 44 and it has been 
hypothesised that due to their weak association with target mRNA these sRNAs often require 
the aid of the RBP, Hfq 11. Some of the sRNAs that have been shown to associate with the Hfq 
chaperone are listed in Table 2.1.  
Table 2.1: sRNAs that have been shown to associate with the Hfq chaperone. 
sRNA Target Reference 
DicF  Inhibits the cell division gene ftsZ in E.coli 68 
DsrA  Regulates transcription, by means of silencing H-NS nucleoid-
associated protein, and promotes translation efficiency of the stress 
sigma factor rpoS in E.coli. Genes affected: rbsD, argR, ilvI, hns and 
rpoS. 
69,70,71,72,73 
FnrS  Regulates genes mostly associated with aerobic metabolism/ 
response to oxidative stress in E.coli. 
Genes affected: adhP, cydD, mqo 
74,75 
GadY  Stabilizes gadX, and acid response transcriptional regulator, mRNA 
in E.coli. 
76 
GcvB  This sRNA is found in a range of bacteria. Genes been shown to be 
targets: Oppa and DppA (transport oligopeptides and dipeptides 
respectively), gltL, argT, stm, livJ, brnQ, sstT and cycA (involved in 
amino acid uptake), ilvC, gdhA, thrL and sera (amino acid 
biosynthesis) and PhoPQ (magnesium homeostasis) 
77,78,79,80,81 
IsrJ Affects the efficiency in which the virulence-associated effector 
proteins translocate into non-phagocytic cells in Salmonella 
typhimurium  
82 
MicA/SraD  Targets the OmpA hindering transcription by occluding the 
ribosomal binding site in E.coli. 
83,84 
MicC  Regulates the expression level of the porin protein ompC by 
interacting with the ompC mRNA in E.coli. 
85 
MicF  Is involved in regulation of stress response by controlling the of the 
outer membrane porin gene ompF in E.coli and related bacteria. 
86 
OmrA/OmrB/RygA/RygB
/SraE  
Is a family of sRNAs that negatively regulate several outer 
membrane protein genes: cirA, CsgD, fecA, fepA and ompT. 
Discovered in E.coli. 
87,88,89 
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OxyS  Is involved in oxidative stress response in E.coli, it’s been shown to 
regulate as many as 40 genes, fhlA being the best example. 
90 
Qrr  Involved in the regulation of quorum sensing in Vibrio species 91,92 
RprA  Regulates translation of the sigma factor rpoS by occluding the 
ribosomal binding site. It also been shown to repress the protein 
coding genes csgD and ydaM (biofilm formation) 
93,94,95 
RybB  Increases the rate of degradation of omp mRNAs in response to 
stress. 
96 
RydC  Regulate the yejABEF mRNA that produces and ABC transporter 
protein. 
97 
RyeB  Identified in E.coli, RyeB is thought to work in a concerted manner 
with SraC/RyeA sRNA because the 2 sequences overlap 
98,10 
CyaR  E.coli derived, represses the porin OmpX in Salmonella 99 
RyhB/Sral  Down regulates set of iron-dependant and iron-storing proteins 100,25  
SgrS  Is activated during glucose-phosphate response and associated with 
intracellular accumulation of glucose-6-phosphate assisting cells in 
recovering from glucose-phosphate stress by repressing the ptsG 
mRNA translation. 
101,102,103,104 
Spot 42  Regulates the galactose operon by binding to the galK gene it also 
affects DNA polymerase 1 
105,106 
SraH/ArcZ/RyhA  In Salmonella it has been shown to regulate the expression of the 
protein involved in serine uptake, sdaCB and tpx (involved in 
oxidative response). 
107,108 
GlmZ/SraJ  Positively aids in the transcription of GlmS mRNA. 109,110,111,112, 
SroB/MicM/RybC A study implicates this sRNA in negative regulation of the outer 
membrane protein YbfM by binding to the ybfM mRNA. It also 
regulates the DpiA/DpiB two-component system. 
113,114 
SroC  Found in several Enterobacterial species and function is unknown (130) 
 
2.5 sRNAs AFFECT RNA STABILITY, RNASE ACTIVITY AND RNA 
MODIFICATION 
Prokaryotic mRNA is less stable than eukaryotic mRNA, allowing prokaryotic cells to rapidly 
adapt to environmental changes 47. In addition to transcriptional regulation, gene regulation can 
also occur at the level of control of RNA stability and degradation, both which affects 
translation processes. Part of this mRNA instability is attributed to the activity of endo-
ribonucleases (RNases). RNases, some of which are part of toxin-antitoxin systems, cleave 
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RNA at specific sites.  They are an important part of the gene regulation machinery operating 
at the post-transcriptional level and are involved in various aspects of RNA metabolism 
including processing, maturation and degradation of mRNA 116. EndoRNases initialise RNA 
degradation by cleaving RNA into small fragments which are further degraded by exoRNases 
47. An example in M. tb is the rnc–encoded RNase III enzyme that functions in ribosomal RNA 
(rRNA) processing, mRNA maturation and degradation, small nuclear RNA (snRNA/U-RNA) 
and small nucleolar RNA (snoRNA) processing, and RNA interference 117.  
M. tb RNase is homologous to E.coli RNases, though their mechanism of action differs. In M. 
tb, RNaseE digests a smaller portion of the A/U rich sequences of mRNA transcripts 118. It also 
has a very slow mRNA turnover rate with a half-life of more than 9 minutes meaning that M. 
tb has a slower repression rate compared to other bacteria. Observations that support this 
hypothesis include the presence of stabilizing secondary structures on transcripts as well as the 
high GC content of mycobacteria 119. This could in part explain the relatively slow growth of 
M. tb in comparison to other Mycobacterium species. 
sRNAs play a role in the turnover of mRNA by guiding RNase E to its cleavage site and also 
by allosterically activating the enzyme.  An example is MicC, a 109 nucleotide sRNA that 
regulates expression of the Salmonella outer membrane protein OmpD porin 120. Such sRNAs 
most probably exist in M. tb given the existence of an RNase E homologue 118,121. 
When sRNAs are bound to their target mRNAs, they either activate or inhibit translation 
depending on the position at which they are binding and they also affect stability of the mRNA 
122.  This interaction is also influenced by chaperones such as Hfq as mentioned earlier. Most 
of these Hfq-assisted sRNAs have multiple targets and only a few of these targets have been 
linked to the corresponding sRNA 123.  
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Figure 2.1 The Role of sRNA and Hfq in repressing translation of mRNA. sRNA and Hfq hybridizes to mRNA 
RBS, blocking ribosome and leading to mRNA degradation. 
 
Interactions with the Hfq protein can affect sRNA target in a number of ways. In some cases 
binding of Hfq to target mRNA/sRNA opens up the hair pin secondary structure often formed 
by mRNA (Figure 2.1). This facilitates the dynamics of sRNA-mRNA complex formation by 
de-sequestering occluded sequences necessary for complementation between a sRNA and its 
target mRNA thereby promoting translation 124. This improves interactions between a sRNA 
and target mRNA through Hfq-Hfq interactions 56,125. Degradation is another possible 
consequence of the Hfq/sRNA/mRNA complex 120. This complex could be a Ribosomal 
Binding Site (RBS) occluding factor rendering the mRNA inactive and prone to RNase activity 
(Figure 2.2) 126. In some cases the sRNA-mRNA complex results in  increased RBS 
accessibility thereby increasing/promoting translation as shown in Figure 2.2 72.  
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Figure 2.2 The role of sRNAs in promoting translation of mRNAs. mRNA forms a stem loop secondary structure 
around the ribosomal binding site (RBS) blocking the ribosome. The sRNA–mRNA hybrid formed opens up the mRNA 
secondary structure, exposing the RBS thereby promoting translation of the mRNA. 
 
A large knowledge gap still exists regarding sRNAs regulation, signals for their synthesis and 
degradation and their importance in human pathogens. It is also not clear how the Hfq-sRNA-
mRNA complexes are dissociated to pave way for degradation molecules like the RNases and 
hence more needs to be done to understand sRNAs as regulatory components. 
It has been shown that during normal transcription, sRNAs are continuously degraded but 
degradation is halted upon addition of rifampicin and sRNAs 127. These results therefore 
suggest that the binding of sRNAs to their targets is a signal for their degradation. Rifampicin 
is an anti-bacterial drug that inhibits RNA polymerase activity and consequently halts bacterial 
transcription 128. It is a major part of TB therapy hence its effects on sRNAs deserve attention. 
The sRNA RNAIII was shown not to require the aid of Hfq suggesting that some sRNA activity 
can proceed even in the absence of this molecule 129.  RNAIII is a 514 nucleotide sRNA with 
14 stem-loop foldings. It was originally extracted from Staphylococcus aureus, where it is 
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implicated in controlling synthesis of virulence factors 130. RNAIII has at least 3 known targets, 
hla, spa, and rot mRNAs, with hla encoding alpha-haemolysin which plays a role in the 
bacteria’s pathogenesis processes 131. In hla mRNA the 5’ end is folded, resulting in occlusion 
of the RBS. RNAIII sRNA 5’ binds to the hla 5’ end of the mRNA, exposing the RBS and 
allows translation to take place. spa gene encodes for a 56 kDa MSCRAMM surface protein 
of S. aureus, it is also known as Protein A 132. The formation of a RNAIII-spa mRNA hybrid 
has the opposite effect on translation. It base pairs with the spa mRNA at the RBS region, 
forming a complex that has a high affinity for degradation enzymes; thus promoting the 
degradation of the spa mRNA as illustrated by Figure 2.3 133. RNAIII sequesters the rot mRNA 
in a similar manner as spa mRNA 134. 
A unique and interesting sRNA mechanism of function without the aid of Hfq is one portrayed 
by CsrA (or RsmA) sRNAs. CrsA is a family of protein regulators negatively regulating 
translation in E.coli by binding and sequestering the RBS. The CsrA sRNAs form secondary 
structures (stem-loops) that mimic the mRNA RBS, thereby activating translation of the CrsA 
(RsmA) targets (Figure 2.3) 135. 
It is of interest to note that in a study by Ramos et al they showed that even the Hfq post-
transcriptional processes can also be regulated by sRNAs 136.  
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Figure 2.3: sRNA mediated activation of translation through its interaction with translation regulators. Translation 
regulators bind the RBS on mRNA making it inaccessible to ribosome binding; and blocking translation. Binding of 
sRNA to the translation regulator releases the mRNA enabling translation to occur.  
 
2.6 SMALL RNAs AND THEIR ROLE IN MYCOBACTERIUM SPECIES 
M. tb is one of the most prominent pathogenic bacterial species in the world, however a 
knowledge gap exists regarding the role of sRNAs in M. tb pathogenesis, virulence, stress 
responses and drug sensitivity. Understanding the mechanisms of regulation in M. tb by sRNAs 
will broaden our understanding of TB infection, particularly the poorly understood mechanisms 
involved in drug resistance, persistence and latency.  
The existence of various sRNAs in M. tb, Mycobacterium  bovis (BCG) and Mycobacterium 
smegmatis has been shown by a number of groups 42,66,137–140. It was shown that many sRNAs 
in M. tb are stress-induced, suggestive of a role in adaptation to a hostile host environment 66. 
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Arnvig and Young showed that F6 significantly slowed down growth , B11 also resulted in 
slow bacterial growth with cells showing elongation narrowing the possible functions of B11 
to cell wall synthesis, and/or cell division 66. However Miotto and colleagues showed that most 
antisense sRNAs bind preferentially to genes implicated in two component systems and 
membrane activity, suggesting that sRNAs not only regulate stress responses but are also 
involved in the regulation of normal metabolic processes in M. tb 138. DiChiara and co-workers 
identified 37 sRNAs in M. bovis BCG; 20 homolgoues of these were predicted and 
experimentally confirmed in M. tb, and 17 in M. smegmatis. Eight sRNAs were conserved only 
in BCG and M. tb, thus one can predict potential involvement in virulence, as M. smegmatis is 
considered non-pathogenic 137.  
Li and colleagues showed that some sRNAs are growth-phase dependent.  They identified 12 
trans-encoded and 12 cis-encoded sRNAs in M. smegmatis, which they showed to be 
differentially expressed at exponential phase in comparison to stationary phase. This suggests 
that sRNAs also play a role in physiology and growth 50.  
In a study by Tsai and colleagues, 17 sRNAs were identified in M. smegmatis, of which 9 
homologues were found in M. bovis and 4 in M. tb 140. The roles of these sRNAs need further 
characterisation. 
2.7 CURRENT KNOWLEDGE OF sRNAs AND THEIR INFLUENCE IN 
M.TUBERCULOSIS 
Drug resistance is one of the major obstacles in curbing the global TB pandemic. Not only do 
it require more resources which could have been used to treat drug susceptible TB but also 
successful treatment outcomes are low, particularly in HIV co-infected patients 141,142. Drug 
resistance mechanisms are not comprehensively understood. A few genes of clinical 
significance have been associated with drug resistance and accepted popular dogma suggests 
that mutations in these genes give rise to drug resistance. However, there is evidence that the 
emergence of XDR-TB is the result of accumulating resistance associated with both known 
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and unknown single-nucleotide polymorphisms (SNPs) rather than of mutations in one or a 
few resistance associated genes. This might explain anomalies such as different drug Minimum 
Inhibitory Concentration (MIC) when the same DR mutations are present, as shown by. In this 
study nsSNPS in 72 genes, 28 intergenic regions (IGRs), 11 SNPs and 12 IGR SNPs (Table 
2.2) were uniquely associated with drug-resistant strains of M. tb, and were absent in drug-
sensitive isolates. These observations include both novel and known factors of drug resistance 
143. However it is not clear how these nsSNPs affects drug-sensitive M. tb and therefore wet 
bench experiments are required to test this hypothesis. It is important to note that some of the 
intergenic regions associated with drug resistance in this study encode for sRNAs 143 and in the 
recent view of sRNAs acting as regulatory elements this deserves more attention.   
Table 2.2 IGR SNPs uniquely found in drug resistant M. tuberculosis isolates 143 
IGR Flanking genes Base change/mutation in IGR 
Rv1482c-Rv1483 Hypothetical protein—fabG1 C→T 
Rv1482c-Rv1483 Hypothetical protein—fabG1 C→T 
Rv1482c-Rv1483 Hypothetical protein— fabG1 T→A 
Rv2416c-Rv2417c eis—hypothetical protein C→T 
Rv2427c-Rv2428 proA—ahpC C→T 
Rv2427c-Rv2428 proA—ahpC G→A 
Rv2754c-Rv2755c thyX—hsdS.1 C→T 
Rv2754c-Rv2755c thyX—hsdS.1 G→A 
Rv3185-Rv3186 transposase—transposase T→A 
Rv3185-Rv3186 transposase—transposase T→A 
Rv3793-Rv3794 *embC—embA G→C 
Rv3793-Rv3794 *embC—embA C→AG 
* embA and embC together with embB are part of  gene cluster of Mycobacterium tuberculosis involved in resistance to 
ethambutol. 
 
Stellenbosch University  https://scholar.sun.ac.za
P a g e  | 36 
 
In other bacterial species there are sRNAs that have been associated with drug resistance. In a 
study by Yu and Schneiders, four sRNAs were linked to trigrecycline/tetracycline resistance in 
Salmonella enterica serovar typhimiurium 144. Some Staphylococcus infections cannot be 
treated as a result of the emergence of glycopeptide resistant strains of Staphylococcus aureus 
(S. aureus). Howden and colleagues identified 409 putative sRNAs in S. aureus using RNAseq 
after exposure to four drugs (vancomycin, trigecycline/tetracycline, linezolinal and ceftobipile) 
145. Recently, the sRNA Sprx(RsaOR) has been shown to control a regulator that is involved in 
S. aureus resistance to glycopeptides 146. These results are evidence that sRNAs can be 
involved in bacterial response to antibiotics and therefore play a role in anti-bacterial 
resistance. However, such in-depth studies lack in mycobacteria. 
Some of the described Mycobacterial sRNAs are associated with known drug resistance genes.  
An example is the Mcr3 sRNA which is located upstream of the M. tb rrs gene, known to be 
involved in aminoglycoside resistance 147.  This sRNA is encoded by a region that includes one 
of the two promoters known to drive rrs transcription 137,139.  However, a functional link 
between this sRNA and aminoglycoside resistance has yet to be established.  
What role does the genes flanking or co-transcribed with sRNAs play in M. tb?  A number of 
studies have  identified mutations in pks12 in drug resistant isolates 148. Whether it plays a role 
in drug resistance is however not clear.  In Mycobacterium the gene pks12 is involved in lipid 
metabolism particularly in the biosynthesis and translocation of cell wall surface exposed lipids 
controlling permeability. This gene has been associated with intrinsic resistance to a range of 
antibiotics in the Mycobacterium avium complex 149. Mutations in the pks12 gene were shown 
to induce drug susceptibility. It was also shown that the pks12 homologue in M. tb H37RV also 
play a role in intrinsic drug resistance though with a narrow drug spectrum and moderate effect 
149. Matsunaga and colleagues also showed that deletion of pks12 in M. avium increases drug 
susceptibility, an observation repeated in M. bovis BCG 150. A clue as to how this gene might 
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influence susceptibility to drugs perhaps might be found in its coding region, wherein a 
sequence for a sRNA, ASpks, was found. Its functions are not known but given its coding 
region, which is within the pks12, it could have regulatory effects on this gene and ultimately 
play a role in intrinsic drug resistance. 
A second sRNA is located between the genes embC and embA 42. These genes together with 
embB are essential in M. tb as they are required in cell wall biosynthesis; they encode for the 
synthesis of arabinogalactan and lipoarabinomannan whose biosynthesis is the target of the 
anti-TB drug Ethambutol (EMB) 151.   
More sRNAs directly associated with DR-genes exist and given that the full spectrum of DR-
genes is not entirely known and that not all sRNAs have been identified and assigned function, 
various aspects of drug resistance mechanisms in M. tb remain unexplained. Elucidating the 
link between sRNAs such as Mcr3 and ASpks, and drug sensitivity could translate into novel 
therapeutic approaches. 
Another observation is that base changes in the intergenic region (IGR) upstream of drug 
resistance genes results in low-level drug resistance. Examples of this are the IG regions 
upstream of eis, inhA and katG. Base changes in promoter upstream of the eis gene are known 
to be involved in low-level resistance to the second-line drug kanamycin, while mutations in 
IG regions upstream of inhA and katG promoter are known to result in low-level INH 
resistance. These three examples illustrate how mutations in intergenic regions could affect 
drug resistance in M. tb.  It is therefore worthwhile to explore how mutations in other IGRs 
affect drug sensitivity.  Another example is the mutation in IGR between furA and katG, 
described by Ando and co-workers, and which results in down-regulation of the furA-katG 
mRNA transcript. Ultimately this results in INH resistance 152.  While it is not known if sRNAs 
play a role in the regulation of these genes, these examples make it clear that mutations in 
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IGRs, which could encode sRNAs or sRNA targets, could alter drug sensitivity patterns in M. 
tb.  
An alternative way in which knowledge of sRNAs could be exploited is suggested by the 
observation that the first line drug rifampicin affects sRNA degradation.  As this drug is used 
as one of the first line combination regiment in TB therapy, it is important to know if sRNAs 
in TB are affected in a similar manner. The regulation of sRNA transcription, in response to 
antibiotic therapy had already been demonstrated in other pathogens such as S. aureus, thus it 
is plausible that the same is true in M. tb 145. 
Another interesting observation, from Zhang’s group, is that one gene or IGR could be 
associated with resistance to more than one anti-TB drug, while multiple genes/IGRs could be 
involved in resistance to one drug (Table 2.3) 143. In the case of IGRs encoding sRNAs the 
latter agrees with the view that sRNAs can have multiple targets 123. This could prove to be 
very efficient and also cost effective when identifying new drug targets as one drug will have 
multiple targets.  
Hfq was shown to reduce persistence in E.coli by means of regulating genes involved in 
persistence. Deletion of Hfq under persister conditions induced expression of the genes ybfM 
and dppA/oppA, and overexpression of these genes led to a 28-fold and 12-fold increase in 
persistence respectively 153. It is important to note that these two genes are strongly regulated 
by the sRNAs, MicM and GcvB, respectively 78,113. Deletion of hfq also repressed a number 
of genes and included among these genes is the micC gene encoding and OmpC translation 
regulator sRNA MicC 153 (also found in Salmonella as mentioned earlier). This is particularly 
important in SigH as pathogenic bacteria such as M. tb also have the ability to enter a state of 
persistence thereby evading antibacterial therapy and host immune response. 
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Table 2.3 IGRs associated with specific anti-TB drugs 143 
DRUG IGRs showing coherent association with drug resistance 
Rifampicin & 
Isoniazid 
Rv2754c-Rv2755c hypothetical protein--putative septation inhibitor protein 
Rv3185-Rv3186 transposase--transposase 
Rv3260c-Rv3261 whiB2—fbiA 
Streptomycin Rv1194c-Rv1195 hypothetical protein -- PE13 
Rv2764c-Rv2765 hyA--hypothetical protein 
Rv3185-Rv3186 transposase--transposase 
Rv3260c-Rv3261 whiB2--fbiA 
Rv3862c-Rv3863 whiB6--hypothetical protein 
Ethambutol Rv1080c-Rv1081c greA--hypothetical protein 
Rv1302-Rv1303 rfe--hypothetical protein 
Rv1347c-Rv1348 hypothetical protein--Rv1348 
Rv2733c-Rv2734 Rv2733c--hypothetical protein 
Rv2764c-Rv2765 hyA--hypothetical protein 
Rv3462c-Rv3463 infA--hypothetical protein 
Ofloxacin Rv1080c-Rv1081c greA--hypothetical protein 
Rv1816-Rv1817 transcriptional regulatory protein--hypothetical protein 
Rv3651-Rv3652 hypothetical protein--PE_PGRS60 
Ethionamide Rv0010c-Rv0011c hypothetical protein--putative septation inhibitor protein 
Rv2340c-Rv2341 PE_PGRS39--lppQ 
Rv3260c-Rv3261 whiB2--fbiA 
Rv3862c-Rv3863 whiB6--hypothetical protein 
Kanamycin Rv1042c-Rv1043c S like-2 transposase--hypothetical protein 
Rv1816-Rv1817 transcriptional regulatory protein--hypothetical protein 
Rv1900c-Rv1901 lipJ--cinA 
Rv2208-Rv2209 cobS--integral membrane protein 
Rv3210c-Rv3211 hypothetical protein—rhlE 
Capreomycin Rv0878c-Rv0879c PPE13--trans membrane protein 
Rv0920c-Rv0921 transposase--resolvase 
Rv2068c-Rv2069 blaC--sigC 
Rv2208-Rv2209 cobS--integral membrane protein 
Rv2764c-Rv2765 hyA--hypothetical protein 
Rv3765c-Rv3766 Rv3768c--hypothetical protein 
Rv3796-Rv3797 hypothetical protein--fadE35 
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The significance of persister cells and recurrence of disease, e.g. as seen in TB, is not well 
understood and therefore investigating the role played by sRNAs in persistence is worthwhile. 
Also the link between persister cells and latent infections is not well comprehended and could 
benefit from exploring this new avenue of sRNAs. 
More still needs to be done in M. tb to decode the nature of sRNA activity.   It is also noteworthy 
that a functional homologue for the sRNA chaperone Hfq, which thus far seems to be a major 
role player in the mechanism of action of sRNAs, thus far eludes identification in 
Mycobacteria.   
2.8 COULD sRNAs BE USEFUL FOR ANTIMICROBIAL THERAPY? 
RNases are of interest for their potential use in antimicrobial therapy.  It is already known that 
human RNases 3 and 7, have antimicrobial activity against a wide range of Gram-positive and 
Gram-negative bacteria 154–157. In Pulido’s study, they investigated the effects of these two 
RNases as antimicrobials against Mycobacterium vaccae, a non-pathogenic and rapidly 
growing Mycobacterium species model. Their results showed total growth inhibition induced 
by both RNases citing new avenues for drug development 158.  This shows the potential of 
RNases as antimicrobial effectors. Technologies such as peptide nucleic acids, which is a 
combination of nucleic acid and amino acids are already being investigated as potential ways 
to target and incapacitate sRNA molecules and thereby be used in antibacterial therapy 159. The 
potential usefulness of peptide-nucleic acids (PNA), to interfere with growth had been 
demonstrated in M. smegmatis where depletion of InhA with the aid of PNA resulted in a 
growth defect phenotype 160. Innovation of using sRNAs targeted to drug resistance genes 
could therefore be useful to achieve similar effects, helping to enhance the bactericidal effect 
of current TB drugs.  
Artificial sRNAs have been designed and experimented on in E.coli. sRNA transcripts with 
target recognition sequences as short as 10nt have been shown to induce gene silencing 161. It 
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is therefore important to create sRNAs that can distinguish between human transcripts and also 
bacterial flora from target transcripts. Also, method of delivery of such compounds is important 
since they still have to cross the cell membrane barrier and upon entry they could be subjected 
to degradation by RNases and also effects of molecular chaperones are to be considered. 
Secondary structures formed once the artificial sRNA has entered the cell is important as some 
structures such as bulges and internal loops weakening the effects of the sRNA-mRNA duplex 
161. 
If transcription of a drug resistance-associated gene could be affected by a sRNA mediated 
antimicrobial effector, it would render the bacteria more susceptible to several first and second-
line anti-TB drugs. Conversely, sRNA regulation of drug resistance genes could also enhance 
resistance to antimicrobial compounds. For example, it was shown, in S. aureus, that the SprX 
sRNA influences sensitivity to glycopeptides by down-regulation of the SpoVG protein which 
is known to affect sensitivity to glycopeptides 146. Thus, the possibility exists that targeting of 
sRNAs could be used to achieve the opposite, that is, enhance sensitivity to a drug 146.  Over 
the years it has been noted that the introduction of new drugs has been coupled with evolution 
of new mutations in the bacteria rendering the new drugs once again ineffective. Ineffective 
use of drugs is one of the reasons for the constant evolution of drug resistance in M. tb and 
therefore policies have to be implemented to protect current drugs before the future antibiotics 
can be introduced. 
Another reason why regulation by sRNAs might be a useful target for developing novel 
antimicrobial strategies is that many virulence genes, antimicrobial drug targets and metabolic 
pathways in M. tb and M. bovis are operonically encoded. Targeting operons is highly efficient 
as one drug could be used to disrupt transcription of multiple genes which share a promoter. 
sRNAs act as regulators and therefore could be exploited to induce such inhibitory effect in 
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organisms. An example is the mce operon (mce1-mce4) of M. tb which is a virulence-associated 
operon (important for bacterial entry into mammalian cells) 162 
2.9 CONCLUSION 
 Gene regulation by sRNAs, and its potential involvement in drug resistance development, is 
under investigation in bacteria. It is not exactly clear how the different sRNAs in M. tb and 
other micro-organisms find their target(s) and this review has shown the significance these 
sRNAs have on bacterial survival. Exploring these sRNAs may reveal hidden aspects regarding 
host-pathogen interactions for instance during latent TB infection. Latent TB, of with which 
one-third of the world’s population is infected, is one of the major obstacles in curbing TB 
infection 163. Identification of novel regulatory mechanisms associated with latent TB can lead 
to better TB diagnosis and treatment. Much about drug resistance mechanisms has been 
uncovered using traditional methods. However, new avenues need to be investigated to fully 
understand these mechanisms and identify novel drug targets and also improve or revive the 
efficacy of existing drugs.  This review highlights how sRNAs potentially could be exploited 
as antimicrobials by manipulating their regulatory effects on gene expression. They also can 
be used to aid the current drugs by altering the regulation mechanisms of DR-genes thereby 
rendering drug resistant species susceptible to the old drugs. It is therefore worthwhile to 
explore this avenue further. 
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MATERIALS AND METHODS 
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3.1. PREPARATION OF BACTERIAL STOCKS, CULTURE MEDIA AND 
CHEMICALS 
Strain selection 
Mycobacterium smegmatis (accession: NC_008596.1 GI: 118467340) was used as a model 
organism for some aspects of this study.  This bacterium is an acid-fast bacterium of the genus 
Mycobacterium. It is generally regarded as a non-pathogenic strain and can cause disease 
mainly in immune-compromised persons 164. It is fast growing (compared to other 
mycobacteria) and shares many characteristics with M. tb including the complex cell wall 
structure and more than 2000 protein homologues, making it an ideal model for M. tb studies. 
M. smegmatis is widely used as a model to study genes and proteins of pathogenic members of 
the mycobacteria. M. smegmatis strain mc2155 was chosen for our cloning studies. M. tb strain 
H37Rv (accession: AL123456.3 GI: 444893469) was used in the sRNA expression 
experiments as well as for preparation of genomic DNA to use as template in PCR reactions. 
E.coli strain DH5 (NZ_JRYM01000004.1 GI: 817646645) was used in the cloning 
experiments. 
Media and chemicals 
Luria Broth (LB) media was prepared by dissolving 20g of LB lyophilised powder (Sigma-
Aldrich) in 1000ml distilled H2O (dH2O) and sterilised by autoclaving. To make LB agar plates 
15g of Bacteriological agar powder (Sigma-Aldrich) was added to the LB broth before 
autoclaving. Appropriate drugs were added after cooling media/agar to a temperature of 
approximately 60oC.  
7H9-ADC broth, used to culture mycobacteria, was made by mixing the following: 4.7g 
lyophilised Middlebrook 7H9 broth base (BD Diagnostics, USA), 900ml dH2O, 4ml of 50% 
glycerol and 2.5ml 20% Tween-80. The mixture was autoclaved and 100ml of Middlebrook 
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albumin-dextrose-catalase (ADC) growth supplement was added after the autoclaved broth was 
cooled down. The resulting mixture was filtered and stored at 4ºC. The ADC used in making 
the 7H9-ADC broth was made mixing 25g of BSA powder, 10g glucose, 750p.l catalase (20mg 
protein/ml, Sigma-Aldrich. Co. LLC) and 500ml H2O. The mixture is stirred for 2-3 hours on 
a magnetic stirrer, after which it is filtered (TPP Filtermax vacuum filters, Zellkultur und 
Labortechnologie Switzerland) and aliquoted, under sterile conditions, into 50ml tubes 
The relevant antibiotics depended on the particular experiments. Ampicillin was prepared as 
100mg/ml stocks by dissolving the powder in deionised water, followed by filter sterilisation. 
Hygromycin B (Thermo-Fischer Scientific, USA) was purchased as a liquid, in a concentration 
of 50mg/ml. Final drug concentrations used were 100µg/ml for ampicillin and Hygromycin B 
at 100µg/ml for E.coli experiments, or 50µg/ml for M. smegmatis.  The drugs isoniazid (INH) 
and kanamycin (KAN) were made by dissolving 100mg of the appropriate powder, in double 
distilled H2O (ddH2O). The flouroquinolones, Ofloxacin (OFL) and Moxifloxacin (MOX), 
were prepared by dissolving100mg of the powder in 3ml alkaline water (1N NaOH in 7ml of 
dH2O).  Antibiotics were sterilised by filtration through a 0.22µm filter. For both drugs a stock 
concentration of 10mg/ml was made in a total volume of 10ml and was stored at -20ºC until 
use.  
Preparation of stock cultures and competent cells 
M. smegmatis cryo-frozen stock cultures were obtained from stocks in our laboratory. These 
were inoculated into 10ml 7H9-ADC media.  Cultures were incubated overnight at 37ºC in an 
incubator with a rotating platform in order to enable proper aeration of cultures. Thereafter  
1ml of each pre-culture was sub-cultured into 100ml 7H9-ADC media and incubated  at 37ºC 
until the optical density at 600nm (OD600nm, as measured in a light spectrophotometer) of ~1 
or slightly greater is reached. Multiple 200µl aliquots were taken from this culture, mixed with 
10% glycerol and stored at -80ºC until use. M. tb H37Rv stock cultures were used in a similar 
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manner to prepare frozen stocks, except that each set of cultures took approximately one week 
to reach an OD of ~1, and cultures were left in a stationary position during incubation, and not 
shaken on a rotating platform. All M. tb culturing was performed in the biosafety level 3 
laboratory of the department. 
Preparation of electro-competent cells 
i)  E.coli chemically competent cells 
Chemically competent E.coli cells where prepared, as previously described 165, by inoculating 
1ul of E.coli DH5α cells into 5ml of LB broth. Cultures were incubated at 37˚C overnight (~16 
hours), with shaking for good aeration. The overnight culture was diluted 1:100 (5ml: 500ml), 
in fresh LB media, and incubated at 37˚C again until OD600nm = 0.3-0.4. These log phase cells 
were then transferred into 50ml centrifuge tubes and centrifuged, in a temperature regulated 
centrifuge (Eppendorf centrifuge 5810R by Eppendorf® USA) set to 4oC; at speed 4000rpm 
for 10 min. Cells were resuspended in 50ml of ice-cold MgCl2 and incubated on ice for 30 
minutes. Centrifugation was repeated, at 4˚C for 10 minutes, after which cells were 
resuspended in 5ml ice-cold buffer (0.05 mM CaCl2-15% glycerol). These chemically 
competent cells were aliquoted, 200µl, in pre-cooled 1.5ml micro centrifuge tubes and stored 
at -80˚C. 
ii) M. smegmatis mc2155 electro-competent cells 
A pre-culture was prepared by inoculating 5ml of 7H9-ADC with 100µl of a glycerol stock and 
incubated at 37°C with shaking. After this culture had grown to late log phase, that is actively 
growing cells, we inoculated 1ml of the culture into 100ml of 7H9-ADC broth. The culture 
was incubated until it had reached an OD600nm of ~1 or slightly greater.  Ziehl Neelsen-staining 
(ZN-stain) was done according to a previously describe procedure 166 on sample cells to ensure 
no contamination occurred during growth.  Cells (in 50ml aliquots) were harvested by low 
speed centrifugation (4000rpm) for 10min at 4oC. All steps were performed on ice and in the 
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temperature controlled centrifuge. Supernatants were discarded and cells resuspended carefully 
first in a small amount of 10% glycerol (~3ml) by pipetting up and down. This was done to 
avoid the creation of bubbles and flocculation during subsequent spins. After the cells were 
resuspended, the volume was made up to 100ml and the harvesting procedure repeated as 
follows: 50ml (2nd wash), 20ml (3rd wash) and 10ml (final wash). After the final wash, cells 
were resuspended in approximately 3-5ml of pure water, whereafter aliquoted  into 400ul for 
electroporation purposes 167–169. 
iii) Gel electrophoresis reagents and equipment. 
50x TAE (Tri-Acetate-EDTA, Thermo Fisher Scientific USA) buffer was prepared as 
previously described, and used at a 1x TAE concentration for DNA gel electrophoreses170. 
For denaturing RNA gel electrophoresis, agarose gels were prepared in 1x  3-(N-morpholino) 
propane sulfonic acid (MOPS) Buffer and denaturing gel conditions using formamide and 
formalin was used, as previously described 171. 
Nucleic acids were visualised by the incorporation of ethidium bromide [4µl (of a 10mg/ml 
stock solution) per 250ml agarose gel], and visualised under UV light at 240nm. When PCR 
products were used for cloning, bands were visualised with long range UV light or with a blue 
light transilluminator (Syngene).  DNA bands were excised and purified from gel slices using 
the Zymoclean DNA gel recover kit (Zymoresearch, USA). 
3.2 ANALYSIS OF M. SMEGMATIS GROWTH AND DRUG SENSITIVITY 
Firstly, a M. smegmatis growth experiment was done to assess the growth pattern of the 
Mycobacterium under the conditions needed for the antibiotic sensitivity assays and 
transcription assays to be done. Starter cultures were prepared by inoculating 200µl aliquots 
(from frozen stocks) into 10ml 7H9 broth and culturing at 37ºC for 18-20 hours.   Starter 
cultures were used to inoculate 200ml of 7H9 culture media, adding appropriately calculated 
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volumes to achieve the same starting (time= 0) optical density for all biological replicate 
cultures. Optical densities were assessed at 600nm (OD600nm) in a spectrophotometer (Ultrospec 
4051, LKB Biochrom).  Cultures were grown at a temperature of 37ºC, with aeration in a shaker 
incubator (Orbital shaker incubator LM530, Yihder.Co.LTD), and the optical densities 
monitored for a period of 2 days. OD600nm readings were taken every 3 hours by mixing 500µl 
of culture with 500µl of 7H9 in a disposable cuvette. The resulting values were multiplied by 
2 to obtain the OD600nm reading of cultures. The mean values and standard errors were 
calculated from three independent biological experiments and used to plot growth curves. 
3.3 DETERMINATION OF MINIMUM INHIBITORY CONCENTRATION (MIC) OF 
M. SMEGMATIS 
To assess what concentration of various TB drugs would be lethal and sub-lethal the M. 
smegmatis strain mc2155 was exposed to various concentrations of INH, OFL, MOX and KAN. 
For this purpose, the bacterium was grown in 7H9-ADC as described for the growth curve until 
an optical density representing the mid-log phase of growth.  At this point, the cultures were 
split into 20ml cultures and the antibiotics added to obtain various concentrations, Table 3.1. 
  Table 3.1 Concentrations tested to obtain sub-lethal drug concentrations for exposure experiments 
 
Aliquots of 1ml each were taken from cultures at different time-points to assess cell death. For 
this purpose, serial dilutions were made (10-1 – 10-7) from the aliquots and 10 µl aliquots (from 
serial dilutions) spotted onto antibiotic-free LB Agar (Figure 5.4).  The growth, or lack thereof, 
Drug Concentration of drug  (µg/ml) 
Ofloxacin 0.00 1.00 1.50 2.00 3.00 
Kanamycin 0.00 0.20 0.50 0.80 1.40 
Moxifloxacin 0.00 0.03 0.05 0.10 0.20 
Isoniazid 0.00 10.00 18.00 24.00 30.00 
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on these plates, after two days of growth at 37oC, were used to calculate MICs as reported in 
Table 5.4. 
3.4 BIO-INFORMATIC ANALYSIS OF M. TUBERCULOSIS sRNA GENES AND 
INTERGENIC REGIONS 
Previous studies have identified putative sRNAs in various mycobacteria (see literature 
review). The data from these studies, combined with published literature on mycobacterial 
sRNAs was used to search for potential associations between drug resistant M. tb clinical 
isolates and published sRNAs. For this purpose, an established genomic database (whole 
genome data derived from clinical M. tb isolates) was scrutinised for the presence of known 
sRNA genes and intergenic regions that were significantly associated with drug resistance, as 
defined in a previous unpublished study. The strains in this genomic database represent a cohort 
of South African TB patients in the Western and Eastern Cape provinces, ranging from drug 
susceptible strains to XDR strains. This bank is hosted by the Department of Biomedical 
Sciences Division of Molecular Biology at Stellenbosch University. 
An in-house python script which was developed by Ruben van der Merwe (unpublished data) 
which closely follows the GATK protocol (genome analysis toolkit best practices 
https://www.broadinstitute.org/gatk/guide/best-practices) was used to screen for SNPs in 
previously identified sRNA regions.  The M. tb strain H37Rv (accession: 
AL123456.3 GI: 444893469) was used as the reference genome in this analysis. The reads 
were obtained from the Illumina platform and three mappers (BWA, Novoalign, and SMALT) 
were used 172,173. Only SNPs appearing on all platforms were regarded as high confidence 
SNPs. Additional data obtained included strain family, drug resistance patterns of each isolate 
etc.  
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3.5 EXPRESSION OF M. TUBERCULOSIS sRNA FRAGMENTS IN M. SMEGMATIS 
AND INVESTIGATION OF ITS EFFECT ON PHENOTYPE  
Selection of sRNA candidates 
Relevant DNA sequences of sRNA fragments were obtained using Tuberculist and TB 
Database (TBDB).  
Cloning strategies 
For phenotypical studies, the three candidates were first cloned (STRATEGY 1) into plasmids 
pMV306 integrating vector and transformed into M. smegmatis wild-type cells.  
 
Generated PCR products on the plasmid contained the sRNA coding sequence as well as 
approximately 50-100bp on either side. An assessment was then done to investigate the effect 
this expression would have on the growth rate of M. smegmatis and also on its drug resistance 
profile against different drugs (KAN and MOX). 
In the second cloning strategy (STRATEGY 2), a plasmid containing a controllable promoter, 
and the ability to integrate at the attB site of M. smegmatis were first constructed.  PCR 
products of the sRNAs were then cloned behind the controllable promoter and constructs 
transformed into the target bacterium. The newly constructed plasmid contained (1) a Tet 
operator, (2) the pmyc1tetO fragment with a promoter to regulate the Tet ON/Off system in 
mycobacteria, and which was obtained from pSE100 expression plasmid, and (3) a fragment 
encoding for an integrase from pMV306 integrating plasmid.  
PCR amplification of sRNAs for use in cloning experiments 
PCR products of the three candidates, mpr6, mcr3 and ASpks (Figure 3.1), were generated for use 
in downstream cloning experiments. It is important to note that the sRNA fragments contain 
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surrounding nucleotides so as to ensure no cleavage of the actual sRNA occurred when carrying 
out restriction digestion reactions. Secondly, since we have no knowledge of potential cleavage 
and post-transcriptional processing of these candidates, we decided to allow extra bases in case 
there was post-transcriptional processing. 
All primers for this study were designed using the Primer 3 program 174 and using the whole genome 
sequence of the reference strain H37Rv as the template for primer design. Restriction sites for 
EcoRV and HindIII restrictions sites were added on the ends of sequences to facilitate 
restriction endonuclease digestion and cloning (Table 3.2). 
Table 3.2 Primers used to amplify sRNA candidates  
Primer Sequence (5’-3’) 
Asks (full) 
Forward 
Reverse 
GGAATTCGATATCAAGCTTGATCACCCCGGCCAC  
 
TAGCCTAAGCTTGATGGGGGATCCGATTGAGGC 
 
 
Mpr6 
Forward 
reverse 
GGAATTCGATATCAAGAGCGCACCCCGAACATGG  
 
TAGCCTAAGCTTGATCGATGGCCTCGATTGACAGG 
 
Mcr3 
Forward 
 
Reverse 
GGAATTCGATATCAAGCCGAGGTCCACGATGTATTCC 
 
TAGCCTAAGCTTGATTTTGGAAAAGGGAGCCAAAGG 
*Restriction sites  for EcoRV (gatatc) and HindIII (aagctt) are underlined. 
 
PCR amplification reaction was set up using the Thermo Scientific Long PCR Enzyme Mix. 
This mix contains a thermostable Taq high fidelity DNA polymerase with proof reading 
activity. The Long PCR Enzyme Mix generates amplicons which are 3'-dA tailed. An M. tb 
crude boiled DNA template was used for amplification of the sRNA regions using the above 
mentioned modified primers. The amplification reaction was set up in 25µl reactions which 
consisted of 2.5µl Long Buffer, 2.5µl of 2.5nM dNTPs, 2.5µl forward primer, 2.5µl reverse 
primer, 11.75µl ddH2O, 3µl DNA template and 0.25µl of the Long PCR Taq high fidelity 
polymerase. 
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Thermocycler PCR conditions for a one step-Long PCR were set up as described in Figure 3.1. 
 
Figure 3.1 Thermo cycling reaction conditions for the Thermo Scientific long PCR used to amplify the sRNA using 
primers with restriction sites. DNA template denaturation was done at 94°C for 3 minutes, extension/elongation step 
was performed at 68°C for 35 two minute cycles, final elongation step was for 10 minutes and a final hold step was 
added at a temperature of 4°C. 
 
Products were analysed with agarose gel electrophoreses to verify the size. Electrophoresis of 
the PCR products was performed on a 1% agarose gel with ethidium bromide (4µl of 10mg/ml 
per 250ml agarose gel), and visualised under UV light at 240nm. Thereafter it was sequenced 
using Sanger sequencing at Central Analytical Facilities (CAF) Stellenbosch University to 
verify the sequence and homology to published sequences (H37Rv as reference genome). 
When PCR products were used for cloning, bands were visualised with long range UV light, 
excised from gels and purified using the Zymoclean DNA gel recover kit (Zymoresearch, 
California, USA). 
 
Cloning Strategy 1: Expression of sRNAs using pMV306 plasmid 
Construction of pMV306 mcr3/mpr6/ASpks plasmid 
Multiple PCR reactions were set up to ensure that excess product is available for purification, 
restriction reactions and final purification steps.  PCR products were purified with the 
Zymoclean DNA gel recover kit before restriction enzyme digestion. The restriction digestion 
reactions contained 16µl of the cleaned sRNA PCR product (~1.5µg), 2µl of 10X reaction 
buffer and 1µl of EcoRV and HindIII restriction enzymes. The mixture was incubated at 37˚C 
for 16 hours to further increase the chance of digestion as a large amount of PCR product was 
being used. Upon completion of digestion the mixture was cleaned up using the Zymoclean 
DNA gel recover kit.  
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A digestion reaction to linearize pMV306 was set up as follow: 1µl of each restriction (10U 
each) enzyme HindIII and EcoRV, 2µl of 10 X reaction buffer and 16µl of the pMV306 
plasmid. The digested plasmid was run on a gel and purified using the Zymoclean DNA gel 
recovery kit. 
Ligations reactions 
The linearized pMV306 fragment was ligated to each of the sRNAs (mpr6, mcr3 and ASpks) 
PCR product in the following reaction: 1µl pMV306 plasmid (approximately 100ng), 7µl 
purified PCR product (50-100ng), 1µl H2O, 10µl of 2X ligation buffer and 1µl of T4 DNA 
ligase. The ligation mixture was incubated at 22˚C for 20 minutes prior to transformation.  
Transformation of prepared new constructs  
The ligation mixtures were used to transform the chemical competent E.coli cells by mixing 
3µl of respective ligation mixtures and 200µl of bacterial cells.  Transformants were selected 
by plating on LB agar plates containing 100µg/ml of the antibiotic Hygromycin B and 
incubated at 37ºC over-night (~16 hours). 
Single colonies were picked and inoculated into 5ml LB broth (plus 5µl Hygromycin B) and 
grown at 37˚C on a shaker for ~16 hours. The presence of inserts was confirmed with colony 
PCR. A schematic diagram for the construction of pMV306-sRNA plasmid is shown in Figure 
3.2. 
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Figure 1.2 A schematic presentation of how the pMV306-sRNA plasmids were made. a) PCR with modified primers 
followed by digestion of the PCR product with EcoRV and HindIII restriction enzyme, b) pMV306 plasmid linearized 
by digestion with EcoRV and HindIII restriction enzyme, c) ligation of each sRNA to linearized pMV306 plasmid 
followed by transformation into E.coli cells 
 
Transformation of M. smegmatis 
The pMV306 + insert plasmid constructs for each sRNA were used to transform electro-
competent M. smegmatis cells. Approximately 3µl (300ng) of the plasmid (pMV306-
mcr3/mpr6/ASpks/wild type WT) was used to transform 400µl of electro-competent M. 
smegmatis cells previously described 167,168. Cells with no added DNA were used as negative 
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control and cells with pMV306 wild type plasmid served as positive controls. The plasmid/ice-
cold cell mixture was pipetted into a cold electroporation cuvette and transformed using the 
electroporation conditions of 2.5kV, 25µF, 1000Ω in the Bio-Rad gene Pulser II electroporator.  
Cells were recovered by immediately adding 600µl of 7H9-ADC media into the cuvette and 
transferring cells into a micro centrifuge tube. Cells were incubated at 37°C for 3hrs or 
overnight before plating on LB agar with Hyg as selection agent.  All transformants, including 
those cells transformed with and without the control plasmid, were serially diluted (10-3 and 
10-6) and 100µl aliquots plated on LB plus Hyg plates. Plates were incubated at 37°C for 
approximately three days. 
Investigation of the effect of sRNA expression using pMV306 plasmid on the growth of 
M. smegmatis 
 
To investigate whether sRNAs have an effect on the growth rate of mycobacterial species, 
colonies from the above transformations for each sRNA were picked and inoculated into 2ml 
of 7H9-ADC broth and vigorously vortexed, prior to incubation at 37˚C with shaking. The 
cultures where grown to OD600nm ~1. Thereafter each culture was sub-cultured into 100ml LB 
broth and the volume of cultures used to inoculate new media for sub culturing was calculated 
to obtain a starter OD600nm of 0.01. The new cultures were then incubated at 37˚C in a shaker 
incubator. Note that the cultures where grown in three biological replicates for each sRNA. 
ODs were taken every 3 hours in a spectrophotometer (Ultrospec 4051, LKB Biochrom). Once 
an OD600nm of ~1 was obtained subsequent cultures were diluted before an OD was taken (500µl 
of culture plus 500µl of 7H9 broth). The resulting values were multiplied by 2 to obtain the 
actual ODs of the cultures. The mean values and standard errors were calculated from the three 
independent biological experiments and used to plot growth curves. 
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Characterisation of drug resistance phenotype of M. smegmatis cells over-expressing the 
sRNAs mcr3, mpr6 and ASpks 
To investigate whether sRNAs had an effect on altering drug resistant phenotypes through their 
proposed involvement in bacterial gene regulation, a drug induction experiment was designed. 
We hypothesised that expressing extra copies of sRNAs can induce a change in drug resistant 
phenotype from resistance to a sensitive phenotype or even just a lower the MIC. We exposed 
mutant M. smegmatis cells to three drugs (KAN, INH and MOX), all of which are currently 
used in various levels of TB therapy. The mutants were exposed to the drugs at MIC levels. 
Two experiment designs were followed: 
Experiment 1: Mutant M. smegmatis cells transformed with pMV306 plasmids with sRNA 
insert were grown in 100ml 7H9-ADC broth plus 100µl of the antibiotic Hygromycin to an 
OD600nm of ~0.5. Thereafter the 100ml cultures were split into 20ml cultures, appropriate drugs 
added at sub-lethal (MIC) concentrations and incubated for 6 hours at 37°C in a shaker 
incubator. To monitor any growth (indicating an altered resistance phenotype), aliquots of 1ml 
each were taken from the cultures, serial dilutions made (10-0-10-5). 10µl aliquots were spotted 
onto antibiotic-free LB agar plates (Figure3.3) and incubated for 3 days. Figure 3.3 shows a 
schematic representation of the experiment. Experiments were repeated to obtain three 
biological replicates of each drug treatment. 
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Figure 3.3 Drug induction experiment 1 schematic representation. Aliquots of 1ml each were taken from the cultures, 
serial dilutions made (10-0-10-5). 10µl aliquots were spotted onto antibiotic-free LB agar plates 
 
Experiment 2: Mutant M. smegmatis cells transformed with pMV306 plasmids with sRNA 
insert were grown in 100ml 7H9-ADC broth plus 100µl of the antibiotic Hygromycin B to an 
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OD600nm of ~0.5. Thereafter the 100 cultures were split into 20ml cultures in three separate 
replicates, appropriate drugs added at sub-lethal concentrations and incubated for 6 hours at 
37°C in a shaker incubator. Thereafter aliquots of the cultures were taken out and sub-cultured 
into fresh antibiotic free 7H9-ADC (20ml) plus hygromycin to make a starter culture of 
OD600nm ~0.01. The culture was incubated at 37°C on a shaker for 3 days. OD600nm readings 
were taken every 6 hours for the first 36hrs to observe any growth, thereafter readings were 
taken every 24 hours. Figure 3.4 shows a schematic representation of the experiment. 
 
Figure 3.4 Drug induction experiment 2 schematic representation. Cultures were incubated at 37°C on a shaker for 3 
days. OD600nm readings were taken every 6 hours for the first 36hrs to observe any growth, thereafter readings were 
taken every 24 hours. 
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Strategy 2: Controlled expression of small RNA in M. smegmatis using a modified plasmid 
containing the Tet ON/OFF promoter expression system 
Many processes in mycobacteria are poorly understood because they are essential for 
mycobacterial growth hence making it a challenge to make knockout mutants or induce 
mutations. The use of controllable promoters on plasmids provides opportunity to regulate the 
level of gene expression in a bacterium thereby providing a way to study such bacterial 
processes. The tetracycline controllable promoter (Tet on and Off system) in plasmid pSE100 
provides such control in mycobacteria 175. The Tet on and off system provides a means of 
regulating the expression of essential genes creating conditional/controllable mutants for these 
essential genes. The inducible gene expression system described here makes use of a 
tetracycline repressor (TetR) that can be repressed or induced by tetracyclines. TetR proteins 
regulate the expression of tetracycline-exporting proteins. TetR proteins are tightly bound to 
Tet-operators (TetO) in the tetA promoter in the absence of tetracycline thereby suppressing 
the transcription of tetA which encodes for a tetracycline exporter. Once tetracycline is 
introduced it binds to TetR resulting in a conformational change leading to the dissociation of 
TetR from TetO. This dissociation paves way for the transcription of the tetracycline exporter 
genes. Guo and colleagues constructed a mycobacterial conditional expression system based 
on the above mechanism by placing TetR responsive operators (TetOs) in regions of a strong 
mycobacterial promoter not essential for promoter activity 175. This resulted in a Pmyc1tetO 
promoter that can be repressed by TetR in M. tb and M. smegmatis. They also showed that the 
use of different anhydrotetracycline concentrations can also control (inducer concentration-
dependent) the level of expression 175. 
However, this vector integrates into mycobacteria at the site of the homologous DNA which is 
present on the plasmid and in the mycobacterial genome. This results in promoter substitution 
of a native mycobacterial promoter with the tetracycline controllable promoter. As sRNAs 
frequently are situated in promoter regions of genes or inside genes, we did not want to interrupt 
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native genes or promoters, but simply have the sRNAs cloned after the TET on/off promoter, 
integrated at the attB site of mycobacteria. Therefore we aimed to create a plasmid containing 
a pSE100 fragment with the TET on/off promoter, combined with the fragment from pMV306, 
which contains the attP site necessary for integration at attB in mycobacteria.  The sRNA could 
then be cloned directly after the controllable promoter, but integration occurs at a site distant 
from the homologous genomic DNA target, i.e. at the attB site. This ensures that a gene is not 
interrupted, which is important in this experiment, as we did not want to do promoter 
replacement or interrupt genes. 
Construction and verification of plasmid pTKL 
The plasmid pTKL was constructed by combining sections of two different plasmids, pSE100 
and pMV306. pSE100 is an expression vector, derivative of a shuttle vector pMS2 and contains 
a Tet operator pmyc1tetO with a mycobacterial promoter 175. It also contains an E.coli (pMB1) 
and a Mycobacteria (pAL500) origin of replication and a multiple cloning site with two 
transcriptional terminators flanking it. PSE100 in E.coli is high copy plasmid and low copy in 
mycobacteria. It carries a Hygromycin cassette conferring bacterial resistance to hygromycin 
(100mg/ml - E.coli, 50mg/ml – mycobacteria). Figure 3.5 shows the pMV306 and pSE100 
plasmid maps.  
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Figure 3.5 pSE100 (5538bp) and pMV306 (4271bp) plasmid maps. A fragment with a Tet operator pmyc1tetO, a 
mycobacterial promoter, a Hygromycin cassette conferring bacterial resistance to hygromycin and origin of replication 
from the pSE100 plasmid was merged to a fragment from pMV306 containing an M. tb integrase sequence. 
 
For the purposes of our experiment we excised a fragment containing the hygromycin B and 
Tet operator cassette from pSE100 using the restriction enzymes ClaI (AT^CGAT) and MscI 
(TGG^CCA). The reaction conditions were as follows; 14µl H2O, 3µl (˜400ng/µl) PSE100 
plasmid, 2µl 2X Tango buffer (Thermo scientific) and 1µl of each enzyme ClaI and MscI 
(Thermo Scientific). The mixture (final volume was 20µl) was incubated at 37˚C for 2 hours. 
The restriction digest was run on a 2% agarose gel for 2 hours at 140Volts, after which the 
desired band (3174bp) was cut out and purified using the Zymoclean DNA gel recover kit 
(Zymoresearch). 
We excised the target fragment containing the integrase sequence of the pMV306 using MscI 
restriction enzyme, thereby cutting on both sides of the integrase fragment in PMV306 plasmid. 
The restriction digest mixture was run on a 2% agarose gel at 120 volts to obtain the desired 
band size of 1344bp. It was cleaned thereafter using the Zymoclean DNA gel recover kit 
(Zymoresearch, California). 
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To combine the two fragments we followed the protocol below and illustrated in Figure 3.6. 
pSE100 fragment was first dephosphorylated by adding 7µl H2O, 10µl pSE100 fragment, 2µl 
Phosphatase Buffer and 1µl Phosphatase. Incubate at 37˚C for 10min, inactivate enzyme at 
75˚C for 2min and chill on ice for 2min. Ligation of the pMV306 fragment to the 
dephosphorylated (dephos) pSE100 fragment was done by adding 4µl of the dephos pSE100, 
5µl pMV306 fragment, 10µl 2X ligation buffer (Thermo Scientific) and 1µl T4 DNA ligase 
(Thermo Scientific) and incubation of the mixture at 22˚C or room temperature (RTM) for 
20min. A Clean up reaction then followed using the Zymoclean Gel clean-up kit (contains a 
DNA binding buffer that can be used to clean up DNA from contaminating reagents. 
Generation of blunt ends of the pSE100 end was done using the restriction digestion enzyme  
ClaI to cut the plasmid. Initial ligations with compatible ends failed. Thus blunt ended 
fragments were generated for further ligations: Mix 8µl pSE100-pMV306 fragment, 10µl 2X 
reaction buffer (Thermo Scientific) and 1µl Blunting enzyme (Thermo Scientific). Incubate at 
70˚C for 5min and chill on ice for 2min. The final Ligation (circularizing the plasmid) and 
transformation reaction was done by adding 1µl T4 DNA ligase to the reaction mixture above 
and incubating at 22˚C or room temperature (RTM) for 20min. The whole mixture (20µl) was 
then used to transform 200 µl of chemical competent E.coli cells which were then plated on 
LB agar hygromycin plates and incubate over night at 37˚C. Refer to appendix 1 for the above 
protocol in point form.  
 
Plasmids were isolated from selected transformants which were cultured overnight, in 5ml LB 
media. The size and orientation of the two fragments in the new plasmid, named pTKL were 
verified by doing a restriction digest reaction with the restriction enzyme BamHI. 
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Figure 3.6 Construction of plasmid pTKL. a) Digestion of the pSE100 with restriction enzymes ClaI and MscI to obtain 
a pSE-fragment containing the PmyctetO gene and the Hygromycin antibiotic resistance cassette, b) Digestion of the 
pMV306 plasmid with the restriction enzyme MscI to obtain the pMV-fragment containing the integrase cassette, c) 
dephosphorylation of the pSE-fragment, d) ligation of the two fragments, e) clean-up with the Zymoclean DNA 
recovery kit to remove reagents that can inhibit downstream steps, f) blunting of the pSE-fragment cut with ClaI 
followed by g) ligation of the blunt end to the pMV-fragment resulting in a circular plasmid. Finally h) the plasmid is 
then transformed into E.coli to obtain more copies of the plasmid. 
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Construction of pTKL-derived constructs containing sRNA genes 
After obtaining the desired plasmid, 16µl of the plasmid pTKL was linearized by digestion 
with 1µl of EcoRV and 1µl of HindIII restriction enzyme for compatibility and easy ligation 
with the inserts.  
The digested plasmid was visualised on a 1% agarose gel and cut out under white light to avoid 
prolonged UV exposure which can induce mutations. The cut out fragments were cleaned up 
with the Zymoclean Gel DNA Recovery Kit recovering approximately 90ng/µl of cut plasmid. 
For ligation of digested PCR sRNA insert (prior cleaned by the Zymoclean DNA recovery Kit 
as in over-expression experiments above) to linearized pTKL plasmid the reaction consisted of 
1µl H2O, 7µl of the digested insert, 1µl linearized pTKL plasmid, 10µl 2X reaction buffer and 
1µl of T4 DNA ligase (illustrated in Figure 3.7). Incubation was for 30 minutes at 22˚C. The 
ligation controls included a wild type pTKL plasmid digested with HindIII restriction enzyme 
which, after addition of ligation reaction reagents, would re-ligate and form colonies on plates 
with hygromycin confirming ligation efficiency. To confirm that the linearized pTKL plasmid 
used in ligation of the sRNA inserts did not self-ligate a ligation reaction was set up consisting 
of 5µl of H2O, 4µl of the linearized pTKL plasmid (using EcoRV and HindIII), and 10µl 10X 
ligation/reaction buffer and 1µl T4 DNA ligase. No colonies were expected on the plates with 
hygromycin, additionally confirming that whatever is seen on the experiment plates was pTKL 
plasmid plus insert. All the ligation reaction mixtures for experiment, positive and negative 
controls were used to transform chemical competent E.coli cells, plated on LB hygromycin 
plates and incubated at 37°C overnight (~16hours). Colonies were picked, inoculated into 5ml 
of LB plus 5µl of hygromycin and grown at 37°C on a shaker overnight. 
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Figure 3.7 Schematic representation of how the pTKL-sRNA plasmids were made. a) PCR of with modified primers 
followed by digestion of the PCR product with EcoRV and HindIII restriction enzyme, b) pTKL plasmid linearized by 
digestion with EcoRV and HindIII restriction enzyme, c) ligation of each sRNA to linearized pTKL plasmid followed 
by transformation into E.coli cells. 
 
Part of the culture (2µl) was then used, in a PCR reaction, to confirm the presence of inserts by 
performing a Thermo Scientific Long PCR reaction, set up as described above and with the 
same sRNA primers. The amplification products were run on a 1% gel and visualised under 
UV. The remaining portion of the 5ml culture, with positive confirmation of inserts by PCR, 
was then used to extract plasmid for downstream experiments (yielded ~350ng of plasmid). To 
further confirm the presence of inserts and orientation a restriction digestion reaction was set 
up for the extracted plasmid as follows; 1µl HincII restriction enzyme, 14µl H2O, 2µl 10X 
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restriction buffer and 3µl of each plasmid. The mixture was then incubated at 37°C for 2hrs (or 
overnight), after which it was run on a 1% agarose gel and visualised under UV light. 
 
Characterisation of growth and drug resistance phenotypes of M. smegmatis expressing 
sRNA genes mcr3, mpr6 and ASpks, using the Tet on and off system 
To characterise the effect sRNAs on Mycobacterium physiology, the above constructed pTKL 
plasmids with inserts were used to transform M. smegmatis cells using the method described 
above (to transform pMV306 + inserts into M. smegmatis). The resulting transformed cells 
were cultured in 100ml 7H9 media and plated on agar plates with hygromycin. Repeated 
transformations failed consistently, thus this strategy was abandoned and no further 
experiments could be conducted.  
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CHAPTER 4 
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TUBERCULOSIS USING M. SMEGMATIS 
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4.1 INTRODUCTION 
The conventional method (chloroform/phenol method) for RNA extractions in bacterial RNA 
contains no enrichment for sRNAs. In order to obtain sRNAs initially one would have to extract 
total RNA followed by a gel electrophoresis of the extracted RNA. After the electrophoresis 
the bands of size smaller than 500bp (presumed to be sRNA bands) will be cut out and purified 
to obtain a sRNA enriched sample. Due to the rigidity of the Mycobacterium cell wall it is 
difficult to extract a high yield of quality RNA.  In addition to this problem, sRNAs constitute 
a small proportion of the total RNA and purification from a gel piece results in a significant 
loss of the sRNA. Also, for accurate and reproducible gene expression analysis, it is imperative 
to eliminate the genomic DNA, therefore a DNase step follows, resulting in further loss of the 
sRNAs. It is important to note that the DNase treatment step can also be performed right after 
total RNA extraction prior to gel electrophoresis but still the loss of RNA is inevitable. The 
whole process from total RNA extraction, gel electrophoresis and clean-up to DNase treatment 
is time consuming (4-5 days) and increases the chances of loss of yield and contamination.  
This chapter describes a method in which one can quickly extract and enrich for sRNA, 
including DNase treatment, in fewer steps and a shorter time frame of approximately 4 
hours. 
4.2 SMALL RNA ENRICHMENT PROTOCOL 
We attempted to design a protocol specifically for isolating sRNAs from total RNA without 
using purification of the sRNA bands from agarose gel slices.  The method entailed combining 
the protocols of the FastRNA PRO™ BLUE KIT (Catalog number: 6025-050 MP Biomedicals, 
USA)176, the RNeasy MiniTM Kit (catalog number: 74104, Qiagen, USA)177 and the RNeasy 
MiniEluteTM kit (catalog number: 74204, Qiagen, USA) 178 (detailed below). The first kit was 
used to isolate total RNA, the second to purify and DNase treat RNA and separate the sRNAs 
from the bigger RNA transcripts, whilst the last kit was used to concentrate the sRNAs and 
elute it in a smaller volume of elution buffer or water.  
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4.3 CULTURING OF STRAINS FOR sRNA ISOLATION 
M. smegmatis strains were cultured, with aeration, in 200ml 7H9 media to mid-log phase, 20ml 
of the culture was then distributed into individual flasks. Prior to extraction, RNAprotect 
Reagent from Qiagen (catalogue number: 76526) was added to cultures followed by 5min 
incubation at room temperature. This agent is reported  to avoid changes in bacterial expression 
profiles 179. The cells from these 20ml culture were harvested by centrifugation at 4000rpm 
(Eppendorf Centrifuge 5810 R).  RNA and sRNA extractions were done as described in the 
protocol below.  sRNAs were eluted in 20ul of RNase-free water and stored at -80ºC.  RNA 
was quantitated using the Nanodrop 2000c machine (Nano Drop technologies. Inc. USA). 
4.4 PROTOCOL: 
The cell lysis and first extraction step is done using the FastRNA Blue Kit: 
1. After centrifugation of cultures pellet cells, disrupt cells using the FastRNA blue kit 
protocol 
- Follow the Fast RNA Blue Kit protocol, including the the chloroform extraction 
step;  
The separation of different RNA species is done using the RNEasy Kit: 
2. Transfer the upper phase, obtained from the chloroform step, to a new reaction tube. 
Add 350ul 70% ethanol, vortex vigorously; 
3. Transfer sample into an RNeasy Mini spin column placed in a 2ml collection tube.  
4. Centifuge at ≥8000xg (≥10,000rpm) for 15s at room temperature, COLLECT THE 
FLOW THROUGH (which contains the sRNAs); If you want to isolate the larger RNAs 
from a culture, keep this column and follow the RNEasy protocol to isolate  
5. Add 450ul of 100% ethanol to flow through liquid, vortex to mix; 
 
The enrichment of sRNA steps are now performed on the MiniElute columns: 
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6. Pipette700ul of this mixture into the RNeasy MinElute column, which is placed in a 
2ml collection tube, then centrifuge at ≥8000xg for 15s at rtm 
7. Discard flow through. NB repeat the step until the whole sample has been pipetted into 
the spin column  
8. Do an on-column DNase treatment* 
*On-column DNase treatment was done according to the RNeasy protocol 
(QIAGEN): 
8.1. Pipette 350μl Buffer RWT into the RNeasy Mini Spin Column/ RNeasy MinElute spin 
column and centrifuge for 15 seconds at  ≥8000 x g (≥10,000 rpm). Discard the flow-
through. 
8.2. Add 10μl DNase I stock solution to 70μl Buffer RDD. Mix by gently inverting the 
tube. Do not vortex, as DNase is sensitive to physical shearing and easily inactivated. 
8.3. Pipette the DNase I incubation mix (80μl) directly onto the RNeasy Mini Spin Column 
membrane/ or RNeasy MinElute spin column membrane and place on the bench top at 20–
30°C for 1 hour. 
Note: Make sure to pipet the DNase I incubation mix directly onto the RNeasy membrane. 
DNase digestion will be incomplete if part of the mix sticks to the walls or the O-ring of 
the RNeasy Mini Spin Column/ RNeasy MinElute spin column. 
8.4. Pipette 350μl Buffer RWT into the RNeasy MinElute spin column and centrifuge for 
15s at ≥8000 x g (≥10,000 rpm). Discard the flow-through. 
 Continue with extractions and elution for sRNA at step 9: 
9. Pipette 500ul buffer RPE* into RNeasy MinElute Column. Centrifuge at ≥8000xg for 
15s, discard flow through 
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10. Add 500u1 of 80% ethanol to the RNeasy MinElute column. Centrifuge at 8000 x 
g for 2min to dry column. Discard flow through. 
NB. After centrifugation, remove column from collection tube. Be careful not to 
touch the flow through 
11. Place column into a 2ml collection tube. Open lid and centrifuge at ≥8000xg for 5min 
12. Place column into a 1.5ml collection tube, add 12ul RNase free water onto the spin 
column membrane. Close lid and centrifuge at ≥ 8000xg for 1min to elute sRNA 
enriched fraction. 
- Repeat 12 
13. Store RNA and perform downstream experiments as desired. 
NOTE: On-column DNase treatment to obtain mRNA can also be done on the RNeasy column, 
using the same protocol as above, except that it is done on the RNeasy columns.  
4.5 ANALYSIS OF THE QUALITY OF ISOLATED sRNAs VERIFYING THAT 
ISOLATED sRNAs IS DNA-FREE 
To check for remaining DNA, a standard PCR, using the Hotstar Taq kit from Qiagen 180, was 
done with the following primers; 6247 SF (GTTCTCGGGACGGAACTTG) and 6247 SR1 
(ACCGATCTGGTGAAGGACAC) that amplify a fragment of the msmeg6247 gene, encoding 
for a hypothetical protein of M. smegmatis 174.   
Analysis of RNA quality using denaturing gel electrophoreses 
Denaturing-RNA gel electrophoresis was done according to a previously described protocol,  
to visualise the 3 bacterial mRNA species and the sRNAs 170. 
Testing the extraction protocol in M. tuberculosis 
In this section of the study, we designed an experiment to isolate sRNA transcriptome from M. 
tb that were cultured under a drug-free and drug induced stress environment. The objective of 
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this experiment was to observe if good quality sRNAs can be isolated from stressed cells and 
is useful for downstream reactions such as quantitative reverse transcription PCR (qPCR).  
In this experiment we chose to look at two sRNAs, mcr3 and ASpks, based on their association 
with genes previously published to be involved in drug resistant mechanisms. The mcr3 sRNA 
is located upstream (promoter region) of the M. tb rrs gene, known to be involved in 
aminoglycoside synthesis 147. The rrs gene is widely associated with resistance to the anti-TB 
drug Kanamycin 181. The ASpks sRNA is coded within the pks12 gene which has been shown 
to cause intrinsic resistance to a range of antibiotics in the Mycobacterium  avium complex 182, 
but mutations in this transcript were also associated with drug resistant isolates in previous 
studies.  Kanamycin was chosen as the test drug for the mcr3 sRNA and Moxifloxacin was 
chosen for the ASpks sRNA. Moxifloxacin was chosen as currently it is a promising drug with 
a very high bactericidal activity as a combination drug with first-line drugs and is associated 
with a decrease in the treatment length of drug susceptible TB and MDR TB 183. One of the 
factors that lead to development of resistance is that patients default treatment creating an 
environment for the bacteria to develop resistance conferring mutations, and this is attributed 
by the intolerable length of the treatment (currently 6 months for drug susceptible TB). 
Addition of MOX to the current regimen could improve the efficacy of TB therapy and hence 
it is important to investigate potential drug resistance mechanisms before its use. 
4.6 ISOLATION AND MEASUREMENT OF sRNA LEVELS IN M. TB EXPOSED TO 
SUB-LETHAL CONCENTRATIONS OF KANAMYCIN OR MOXIFLOXACIN 
Six cultures of M. tuberculosis (50ml of 7H9-ADC broth each), were prepared with starting 
inoculums to obtain an optical density of approximately0.05.  When cultures, grown at 37oC, 
reached an optical density of 0.4 to 0.5, two biological replicates each were combined in order 
to obtain a big enough volume for induction experiments.  This volume of 100 ml was split 
into separate culture flasks of 20ml each (Figure 4.1), and antibiotics added as indicated in 
Table 4.1.  One day after the addition of the antibiotics, cells were pelleted, resuspended in 
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1ml of RNAProtect as previously described, and RNA extractions proceeded as described for 
M. smegmatis above.  
 
Figure 4.1 Experimental setup for s RNA extraction from M. tb cultures. In order to increase starter culture two 50ml 
cultures were combined before the drug induction step. 
Pooling of two cultures was done to increase the amount of starter material, as culturing in the 
BSL3 laboratory is limited to 50ml volumes of M. tb per culture tube, and we isolated RNA 
from early log phase cells. 
Table 4.1 Exposure conditions for M. tuberculosis cultures. 
Tube 1 Extraction time  Moxifloxacin final concentration (µg/ml) 
1 Day 0, control 0 
2 After 24hrs, control 0 
3 After 24hrs 0.01 
4 After 24hrs 0.02 
 
Tube   Kanamycin final concentration (µg/ml) 
1 Day 0 control 0 
2 After 24hrs, control 0 
3 After 24hrs 1 
4 After 24hrs 2 
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4.7 qPCR REACTIONS TO ANALYSE IF cDNA CAN BE OBTAINED FROM 
ISOLATED sRNAs 
cDNA Synthesis and PCR reactions  
In preparation for the qPCR, new primers were designed, in order to generate PCR fragments 
of approximately 100bps in length (Table 4.2).  
Table 4.2 sRNA primers used for qPCR. 
Primer Sequence (5’-3’) TM °C Length (bp) 
 
Mcr3 
Forward 
Reverse 
 
CCATTGCCGGATTTGTATTAG 
GTGTGTTTGGTGGTTTCACA 
 
59.33 
57.81 
 
102 
 
 
Asks 
 
Forward 
Reverse 
 
CTGCGTATGACCCATATTCGG
ATCCGATTGAGGCTCAGG 
 
59.02 
60.72 
 
108 
 
  
cDNA synthesis was performed on the extracted RNA samples, using the iScript cDNA 
synthesis kit (catalogue number: 1708890 Bio-Rad laboratories, Inc.), including the random 
hexamers. Reactions contained 50ng of purified RNA, 4µl 5x iScript reaction mix, 1µl iScript 
reverse transcriptase and made up with Nuclease-free water to a final volume of 20µl. The 
reaction mix was incubated for 5 minutes at 25°C, 30 minutes at 42°C and finally 5 minutes at 
85°C to inactivate the iScript reverse transcriptase. For the second step PCR: A master mix was 
made and 18µl aliquots pipetted per well, in a 96-well plate. Each aliquot consisted of 10µl of 
iTaq Universal SyBr green supermix, 0.2µl of the forward primer, 0.2µl of the reverse primer 
and 7.6µl of RNase-free H2O. cDNA, 2µl each, were added per well.  
The 96 well ABgene plate (Thermo Fisher Scientific, Inc., Waltham, MA, USA) was 
centrifuged (3rpm, 10 seconds, room temperature) before PCR was performed on the Bio Rad 
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CFX96™ Real-Time System (Bio Rad C1000™ Thermal Cycler) instrument (Bio Rad 
Laboratories, Inc., Hercules, California, USA). The protocol was as follows: Activation at 95°C 
for 15 minutes, for 40 cycles- Denaturation at 95°C for 15 seconds, Annealing at 60°C for 30 
seconds and Elongation at 72°C for 30 seconds. Lastly a melting curve program (95°C for 0 
seconds, 60°C for 15 seconds, 90°C for 0 seconds with a heating rate of 0.1°C/s) and Cooling 
down program (40°C for 10 seconds) were executed.  
Quantitative analysis  
 
Standard curves were initially constructed using the cDNA derived from the sRNAs. 
Subsequent standard curves were generated using serial dilutions made from M. tb genomic 
DNA. The standard curves were constructed by first making serial dilutions (undiluted DNA 
at concentration of 50ng/µl, 1/10, 1/100, 1/1000, 1/10000, 1/100000, 1/1000000) of a genomic 
DNA sample. The M. tb gene, sigA, usually used as reference gene, was used as a control to 
verify that cDNA was successfully made, albeit from the rRNA.   A linear standard curve was 
plotted using the Bio-Rad CFX96TM Real-Time System (Bio-Rad Laboratories, Inc., USA). 
The relative quantification was not carried out as a result of limited availability of reference 
genes optimised for sRNAs. 
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5.1 BIOINFORMATIC ANALYSIS OF MUTATIONS IN M. tuberculosis sRNA GENES 
AND INTERGENIC REGIONS 
This study investigated sRNAs which were previously associated with drug-resistant M. tb 
drug resistance.  First we verified if mutations in the same species could be identified in a 
genome bank of clinical samples from our local population. We further selected a sub-set for 
further analyses.  These candidates, mpr6, mcr3 and ASpks were selected based on the 
following: 
1. mpr6 is associated with sigE that is part of the sigH regulon which is known to be 
differentially regulated in the presence of INH 184,137. This sRNA is transcriptionally 
associated with sigE (see genomic context, Figure 3.1), thus potentially is also 
differentially regulated by the presence of the drug. 
2. mcr3 is associated with rrs, an essential gene and the main gene associated with 
kanamycin resistance when rrs is mutated 185 (Figure 3.1).  This sRNA is part of the 
rrs, rrl and rrf tri-cistronic operon (Figure 3.1).  
3. The ASpks sRNA was recently associated with drug resistance, when bioinformatics 
analysis revealed that mutations in specific mRNAs clustered uniquely with various 
drug resistant M. tb clinical isolates. This sRNA is found inside the pks12 gene, which 
is significantly associated with drug resistance in M. avium 182. The precise role of 
pks12 in drug resistance is not clear though (Figure 3.1). 
Previous studies have identified regions in the M. tb genome that, in addition to already known 
genes, are associated with drug resistance. In this study we analysed only those previously 
identified regions coding for known and suspected sRNAs. This data set therefore looked at 36 
previously described target regions.  Of these 36 targets, SNPs were identified in 29 targets in 
our genomic bank (Figure 5.1). The largest proportion of isolates that contained a base change 
in a sRNA contained it in a region inside locus Rv2048c.  Rv2048C encodes for polyketide 
synthase 12. Polyketide synthases are increasingly identified in drug resistant M. tb, although 
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the mechanism whereby it influences drug sensitivity  is not clear 150.  All these isolates were 
classified as drug resistant based on drug resistance tests done in our department. 
  
 
Figure 5.1. The percentage of analysed isolates which contain one or more SNP in each sRNA or putative sRNA region. 
 
The following observations were made: 
1. Isolates with SNPs in the different sRNA regions, were drug resistant. The drug 
resistant phenotypes ranged from Rif/INH mono-resistant isolates to XDR isolates 
(Table 5.1).  
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2. Further analysis of the isolates with SNPs and whose genotype was available on the 
database revealed the predominance of the Beijing genotype (69%) (Figure 5.2). 
However, this result might be co-incidental as the majority of isolates in the Western 
Cape region are from this family. This overrepresentation might disappear if more 
isolates from other families are available for analysis. 
3. The sRNA ASpks had the most number of SNPs, (Tables 5.1 and 5.2) in the analyzed 
isolates. This includes strains containing more than one SNP in this candidate. The mcr3 
candidate is also featuring in many of the drug resistant strains. 
 
 
Figure 5.2 The percentage distribution of the M. tb strain families with SNPs in sRNAs. 
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Table 5.1 Association of mutations in sRNAs or intergenic regions of M. tuberculosis with genotype and drug resistance 
patterns. RIF – Rifampicin, INH – isoniazid. 
 Region/sRNA  Intergenic/ 
sRNA 
Drug phenotypes (sensitive/resistance) Families 
Rv0010c-Rv0011c INTERGENIC RIF Mono, Pre XDR, MDR, N/A Beijing X2, F9, EAI 
Rv0466-Rv0467 INTERGENIC RIF Mono (2), MDR, Pre XDR Beijing X4, LCC 
Rv0744c-Rv0745 INTERGENIC  N/A  N/A 
Rv0878c-Rv0879c INTERGENIC RIF Mono (2), INH Mono (3), MDR (4) Beijing, Haarlem, LCC X 12, N/A X2 
Rv0840c-Rv0841 INTERGENIC Rif Mono, INH mono, N/A Beijing, F28 X2 
Rv0908-Rv0909 INTERGENIC N/A N/A 
Rv0920c-Rv0921 INTERGENIC  N/A  N/A 
Rv1042c-Rv1043c INTERGENIC N/A F28 X2 
Rv1194c-Rv1195 INTERGENIC N/A Beijing X2, F11, Haarlem 
Rv1080c-Rv1081c INTERGENIC  N/A  N/A 
Rv1302-Rv1303 INTERGENIC N/A Beijing 
Rv1347c-Rv1348 INTERGENIC  N/A  N/A 
Rv1482c-Rv1483 INTERGENIC RIF Mono (2), INH Mono (3), MDR (6), POLY (2), Pre 
XDR (9), XDR (11), BLANKS (2) 
  
Rv1816-Rv1817 INTERGENIC POLY, N/A Beijing X2, LCC 
Rv1900c-Rv1901 INTERGENIC  N/A  N/A 
Rv2068c-Rv2069 INTERGENIC N/A F11 
Rv2208-Rv2209 INTERGENIC INH Mono Beijing 
Rv2340c-Rv2341 INTERGENIC RIF Mono (12), INH Mono (4), POLY (2), MDR (9), Pre 
XDR (9), XDR (13), BLANKS (15) 
13409 X2, Beijing X54, CAS, EAI, F11, 
F20, Haarlem, LCC 
Rv2416c-Rv2417c INTERGENIC MDR, Pre XDR (3), XDR (2), BLANKS (4) Beijing X5, F11, F26, F28, BLANKS X2 
Rv2427c-Rv2428 INTERGENIC INH Mono (2), MDR (5), BLANKS (7) Beijing X4, CAS, EA1, F11, F20, 
Haarlem, LCC X3, BLANKS X2 
Rv3260c-Rv3261 INTERGENIC RIF Mono (2), INH Mono, MDR, Pre XDR Beijing X3, F11 X2, MIX, BLANKS  
Rv2754c-Rv2755c INTERGENIC MDR, N/A Beijing X2, F28, LCC X2 
Rv3185-Rv3186 INTERGENIC N/A Beijing 
Rv2764c-Rv2765 INTERGENIC N/A F9 
Rv3210c-Rv3211 INTERGENIC N/A Beijing 
Rv3462c-Rv3463 INTERGENIC N/A Beijing 
Rv2733c-Rv2734 INTERGENIC  N/A  N/A 
Rv3793-Rv3794  INTERGENIC MDR (2), Pre XDR LCC X2, F11 
Rv3796-Rv3797  INTERGENIC MDR Haarlem 
Rv3862c-Rv3863  INTERGENIC RIF Mono (25), INH Mono(15), MDR (25), POLY (5), 
Pre XDR (17), XDR (20),  BLANKS (58)  
13409, Beijing X87, CAS, EAI X2, F9 X3, 
F11 X23, F14, F15, F20, F26, F28 X7, 
Haarlem X4, LCC X22, BLANKS X13 
MTB000019 sRNA-mcr3 RIF Mono (26), INH Mono (16), MDR (23), POLY (6), 
Pre XDR (20), XDR (14), BLANKS (66) 
Beijing X78, CAS, EAI, F9 X3, F11 X26, 
F14, F15 X2, F20, F26, F28 X8, Harlem 
X4, LCC X22, mix, blanks X21, 13409 
MTB000064 sRNA-mcr3 RIF Mono (26), INH Mono (15), MDR (35), POLY (4), 
Pre XDR (41), XDR (100), BLANKS (53), XDR (14), 
BLANKS X66 
Beijing X172, CAS X8, EAI, F9 X2, F11 
X18, F15 X2, F20, F26, F28 X7, Haarlem 
X15, LAM X7, LCC X25,MIX, Quebec/s, 
T1 X7, T2, T5 X2, BLANKS X72 
Rv1221-Rv1222 sRNA-mpr6 N/A Beijing, F11 
Rv-0243-Rv0244c sRNA-F6 MDR  N/A 
Rv3651-Rv3652 sRNA-mpr18  N/A  N/A 
Rv2048c sRNA-ASpks RIF Mono (175), INH Mono (78), MDR (224), POLY 
(26), Pre XDR (254), XDR (629), BLANKS (418) 
Beijing X1134, CAS X65, EAI X20, F9 
X14, F11 X98, F15 X29, F20 X8, F26 X8, 
F28 X44, Haarlem X95, LAM X43, LCC 
X122, MIX X6,  Quebec/S X6, T1 X22, T2 
X2, T5 X7, BLANKS X518 
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Table 5.2 SNPs identified in the three sRNA candidates used for wet bench experiments.  
sRNA BASE 
CHANGE 
Frequency 
(Numbers) 
Genomic 
loci 
Notes 
rrs T-C 2 1471644  
 C-T 169 1471659  
mpr6 G-T 2 1365327  
ASpks C-A 143 2295685  
 C-T 11 2295917  
 G-C 306 2296042  
 A-G 34 2296181  
 C-A 9 2296406  
 C-G 10 2296876  
 G-A 5 2297766  
 T-C 5 2297974  
 G-A 317 2297976  
 G-T 88 2298194  
 A-G 302 2300237  
 A-T 279 2300546  
 T-G 283 2300552  
 A-G 282 2300555  
 C-T 3 2300674  
3 isolates had all 4 SNPs, each SNP 2 bases 
from the other 
 T-A 3 2300676 
 T-C 3 2300678 
 G-A 3 2300680 
 T-C 5 2301089  
 G-A 75 2302033  
 C-A 10 2304068  
 A-G 9 2306306  
 T-C 10 2306472  
 T-G 3 2306630  
all 3 SNPs were found in 3 isolates  A-G 3 2306632 
 C-G 3 2306633 
 
 
5.2 ANALYSIS OF M. smegmatis GROWTH AND DRUG SENSITIVITY  
Initial experiments were done to verify the growth pattern of the test strain under the conditions 
used in our assays. From this data (Figure 5.3), it is clear that a mid-log phase is reached 
between 9 and 15 hours, whereafter the growth decelerate as stationary phase ensued. From 
this data, we decided to use an optical density of 1.5 to represent mid-log phase M. smegmatis 
growth which achieved at approximately 12 hrs. 
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Figure 5.3 M. smegmatis growth curve in 7H9 media. A, B, C represents each replicate. 
 
M. smegmatis minimum inhibitory concentration (MIC) determination 
The MICs for the anti-TB drugs INH, KAN, MOX and OFL in M. smegmatis were determined. 
M. smegmatis cells (100ml for each drug) were grown to mid-log phase and split into five 20ml 
cultures. For each drug to be investigated different concentrations were added to the 20ml 
cultures as indicated on (Table 5.2) and incubated at 37°C for 6hrs. As described above, 1ml 
was then taken from these cultures, serial dilutions made and 10µl aliquots spotted onto 
antibiotic free LB agar plates. Plates were incubated for 36hrs. MICs were translated as the 
concentration at which very little to no growth was observed (Figure 5.2) and these values 
recorded in (Table 5.2). 
Sub-lethal concentrations, as shown in Table 5.2, were used in further experiments. 
 
fg 
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Figure 5.4 Determination of drug sensitivity of M. smegmatis. For this assay, serial dilutions were spotted on plate, 
with lowest to highest dilutions from left to right of plates. Represented in figure are results from some of the 
experiments, using INH and Moxifloxacin to illustrate how it was done. A: Bottom row, no drug; middle row, 5µg/ml 
INH; top row, 10µg/ml. B: Bottom row, 20µg/ml; middle row, 30µg/ml INH.  C: .Bottom row, no drug; middle row, 
0.03µg/ml MOX; top row, 0.05µg/ml MOX. D: Bottom row, 0.2µg/ml; middle row, 0.4µg/ml MOX; top row, 0.6µg/ml 
MOX.   The same experiment was done also with Kanamycin and Ofloxacin. 
 
 
 
Table 5.4 MICs for the different drugs and the concentrations to be used in qPCR exposure experiments. 
  
5.3 EXPRESSION OF M. TB sRNAs IN M. SMEGMATIS AND THEIR EFFECT ON 
GROWTH 
Three strategies were followed to assess expression of M. tb sRNA on the phenotype of M. 
smegmatis.  Firstly, direct association with the transcript of a drug-resistance associated gene 
Drug MIC (µg/ml) Concentration (µg/ml)  
determined as sub lethal 
Ofloxacin 0.75 0.5 
Kanamycin 0.5 0.1 
Moxifloxacin 0.03 0.01 
Isoniazid 24 10 
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was used to select the mcr3 sRNA, which is co-transcribed with the rrs gene, which is involved 
in Kanamycin resistance 186.   
 
Figure 5.5 Genomic context of the sRNA mpr6, mcr3 and ASpks. The rrs, or 16S RNA gene is associated with 
kanamycin resistance; the pks12, gene encodes a membrane associated protein, and in which mutations are frequently 
found in drug resistant isolates 150,192. Image was adapted from Tuberculist 191 
An indirect association of a small RNA and drug resistance genes was used to select the mpr6 
sRNA, which  is suspected to play a role in the regulation of sigE, which is known to affect 
katG (involved in INH resistance) transcription 187–190,152. This sRNA is situated in the 
intergenic region between the sigma factor sigE and its anti-sigma factor RseA.  We 
hypothesized that mpr6 works by facilitating the interaction of the two regulatory factors. 
Sigma factors play a role in regulating M. tb response to external stress. SigE is particularly 
important in regulating response to intracellular stress by interacting with genes involved in 
maintaining cell wall integrity. Furthermore, INH targets cell wall mycolic acid formation, the 
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M. tb sigE transcript as part of the sigA regulon was previously shown to increase after exposure 
to INH. 137,184.  The last strategy was to select a candidate identified in previous publications 
as a potential role-player in the development of drug resistance.  For this reason, the ASpks 
sRNA was selected. This sRNA code is found within the pks12 gene, which was previously  
shown to induce intrinsic multiple drug resistance in mycobacterial species, although the 
mechanism is unclear 149,147,191,143,148.  The genomic loci of the sRNA is shown in figure 5.5. 
Two plasmid systems were designed to investigate the effect of sRNAs on the physiology of 
mycobacteria. In these two experiments we aimed at characterising the effect of sRNAs on 
Mycobacterium physiology particularly looking at growth and drug resistance. DNA from a 
wild-type M. tuberculosis sample was successfully used to amplify and clone the sRNA regions 
of interest (mcr3, mpr6 and ASpks). Figure 5.6 shows the gel picture showing positive 
amplification of the desired regions in E.coli transformants of pMV306 constructs. 
Construction of pMV306 and derivative plasmids containing the sRNAs  
In the first strategy we designed a plasmid that allowed us to express each sRNA in M. 
smegmatis, a Mycobacterium model. An assessment was done to investigate the effect this 
over-expression would have on the growth rate of M. smegmatis and also on its drug resistance 
profile against different drugs (KAN, MOX, OFL and INH).  
The amplified sRNAs with attached restriction sites were digested with the respective 
restriction enzymes (EcoRV and HindIII), the same enzymes used to digest pMV306 plasmid 
for cloning (Figure 5.7). 
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Figure 5.6 sRNA PCR amplification of target sRNAs.  Multiple PCRs were performed to ensure enough yields after downstream 
purification steps.    Expected sizes:  mcr3 – 367bp, mpr6 - 351bp and ASpks – 142bp. Lane 9 is a control PCR with no template. We 
used the Gene Ruler 100bp DNA ladder (Catalogue number: SM0241, Thermo Fisher Scientific Inc. USA) 
 
The digested sRNA PCR amplicons were successfully ligated to the linearized pMV306 
plasmid and used to transform E.coli.  
Colonies were picked and inoculated in liquid cultures. Thereafter plasmid extraction was done 
and a PCR done to confirm successful ligation of insert to plasmid (Figure 5.6), and also 
confirmed with restriction digestion reactions. 
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Figure 5.7PCR to confirm successful ligation of insert to plasmids pMV306.  Lanes before the size marker on right contained positive 
control PCRs, where genomic DNA was used as template. 
 
Restriction analysis was used to guide the construction of maps as depicted in Figure 5.8. 
Plasmid maps were constructed using the software developed by Magnus Manske, GENtle 
V1.9.4 193. 
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Figure 5.8 Schematic representation of pMV306-sRNA plasmid generated using GENtle, A) pMV306, B) pMV306-
mcr3, C) pMV306-mpr6, D) pMV306-ASpks. 
 
Electro competent M. smegmatis cells were checked for contamination using ZN-stains, 
showing we used pure cultures for downstream experiments (Figure 5.9). 
 
                                  Figure 5.9 Ziehl Neelsen stain test on M. smegmatis electro-competent cells. 
Stellenbosch University  https://scholar.sun.ac.za
       Page 89 
 
Growth assessment of M. smegmatis after over-expression of sRNAs 
A growth curve experiment was performed to assess if the selected sRNAs had an effect on 
Mycobacterium growth rate. M. smegmatis mutant cells transformed with pMV306 plasmid 
containing a sRNA insert were grown in liquid media and growth rate measured by taking ODs 
at selected time intervals (3 hours) (Table 5.5). These ODs where used to plot growth curves 
for each sRNA (Figure 5.11). In order to assess if the sRNAs had an effect on growth in M. 
smegmatis, controls included M. smegmatis transformed with only pMV306 plasmid in order 
to verify that any change noticed is brought about by the sRNA under investigation. To verify 
that the plasmid itself does not interfere, a negative control, wild-type M. smegmatis culture 
without plasmid, was also included. 
These differences were only seen in the strains with plasmid constructs containing sRNA 
genes, and not in strains transformed with the control plasmid. 
 
 
Figure 5.11 M. smegmatis growth curve showing the growth rate of sRNA transformed cells in comparison to wild-type 
cells. 
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It is clear that the presence of the extra copies of the RNA genes results in later onset of growth, 
with the ODs of control cultures almost tenfold more within three hours, whereas cultures with 
the sRNA copies only reached mid-log after approximately 22 hours. Control cultures also 
reached mid-log phase at about 12.5 hours of growth, whilst the cultures with the sRNA-
expressing plasmids exhibited an OD of maximum 0.5. The onset of stationary phase was also 
much later in the latter cultures (25hrs compared to 15 hours). 
Interestingly, this altered growth of M. smegmatis in the presence of expressed M. tb sRNA 
genes had been described before by Arnvig and co-workers 66. Although this was observed 
with other sRNAs and not these described here, it would suggest that optimal conditions and 
plasmid constructs to assess sRNA function is still not clear, and that tight control of expression 
is needed to observe a real effect in mycobacteria. 
Characterisation of drug resistance phenotypes of M. smegmatis cells over-expressing the 
sRNAs mcr3, mpr6 and ASpks 
Small RNAs have been hypothetically associated with regulatory effects on the genes they 
target. However the mechanism by which these sRNAs function is not known. Here we set out 
to investigate what effect these candidate sRNAs had on the drug resistance profiles associated 
with the genes co-transcribed with or adjacent to them. In the first experiment, described above, 
no growth was seen after exposing the mutant M. smegmatis cells to sub-lethal (MIC) 
concentrations of the respective drugs up to day five  (Figure 5.12). Similar results were 
obtained in experiment 2 involving re-growing drug exposed M. smegmatis cells in liquid 
cultures.  These results suggest that the presence of the extra copies of a sRNA is detrimental 
to the bacterium, with regards to adaptation to antibiotic induced stress. 
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Figure 5.12 Exposure of mutant M. smegmatis cells to sub-lethal (MIC) concentrations. No growth was seen after 
exposing the mutant M. smegmatis cells to sub-lethal (MIC) concentrations of the respective drugs up to day five (B). 
A) Shows the positive control with growth. 
 
As these were the wild type sRNAs, one is tempted to speculate that this observed negative 
effect, if true, would be absent if base changes are present in these sRNAs. 
 
Controlled expression of small RNA in M. smegmatis using a modified plasmid containing 
the Tet ON/OFF promoter expression system 
In an attempt to express the sRNA genes under the influence of a controllable promoter, a 
plasmid was created using the controllable Tet ON/OFF promoter system. However, to prevent 
integration at, and thus interruption of targeted chromosomal areas with functional genes, we 
used the fragment of the pSE100 plasmid 175, containing only the controllable promoter and an 
antibiotic marker.  This fragment was ligated to the fragment from pMV306, which contains 
the integration cassette from the parent plasmid as well as the attP site.  This new construct 
enabled the integration of the plasmid at the bacterial attB site, as opposed to homologous 
recombination at the mycobacterial homologous DNA found on the plasmid and the bacterial 
genome. 
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The pSE100 plasmid cut with the restriction enzymes ClaI and MscI yielded two bands and 
pMV306 cut with MscI also yielded two band and the desired bands, 3174bp and 1344bp 
respectively (Figure 5.13).   
 
Figure 5.13 pSE100 plasmid cut with the restriction enzymes ClaI and MscI. A). Lane 1 and 2 shows the restriction map for pSE100 
plasmid cut by restriction enzymes ClaI and MscI , lane 4 and 5 is the positive control (pMV306 cut by SaII) and lane 7 and 8 is the 
pMV306 plasmid cut by Msc1 for the Integrase fragment. Lane 2 in both gels:top band represent the 3174bp fragment from plasmid 
pSE100; Lane 7 and 8:The 1344bp fragment from plasmid pMV306  was excised as shown  in  B. Lane 3 and 6 are negative controls. 
 
 
The pMV306 fragment could ligate in one of two ways, resulting either in plasmids with 
BamHI restriction fragments of 3383 and 1135bp (Figure 5.14, lane 2), or 4149 and 359 bps 
(Figure 5.14, lanes 5 and 7). However the plasmids in lane 5 and lane 7 were the desired ligates 
and therefore were chosen for downstream experiment (Figures 5.14). Figure 5.15 shows the 
desired ligates in two orientations. 
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Figure 5.14 Restriction enzyme (BamHI) analysis of plasmid pTKL. Lane 3, 6, 8:  plasmid pTKL digested with BamHI. Lanes 1 and 
11, DNA marker, Lanes 2,4,5,7,9 and 10, Plasmids without insert or incorrect sized inserts (the latter potentially from multiple 
ligations of the insert in a single clone).  The plasmid in lane 2 shows a different ligation orientation of the two fragments.  
 
 
Figure 5.15 the plasmid maps (A and B) showing the newly constructed pTKL plasmid in both orientations. The pTKL 
plasmid shown in A was then used for all downstream experiments.  
 
The pTKL plasmid was successfully linearized by digesting it with the restriction enzymes 
EcoRV and HindIII for the purposes of constructing pTKL plasmids containing the sRNAs 
(Figure 5.16) 
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Figure 5.16 plasmid pTKL digested with EcoRV and HindIII restriction enzymes that cut the pTKL plasmid at sites 
one base pair from each other giving a band similar to a linearized pTKL plasmid of 4518bp length. 
The respective sRNAs were ligated to the plasmids and controls added to confirm ligation 
efficiency and that no self-ligation occurred. The controls included a wild type pTKL plasmid 
digested with HindIII restriction enzyme which after addition of ligation reaction reagents 
would re-ligate and form colonies on Hygromycin plates confirming ligation efficiency 
(Figure 5.17). To confirm that the linearized pTKL plasmid used in ligation of the sRNA 
inserts did not self-ligate, a ligation reaction was set up for the linearized pTKL plasmid (using 
EcoRV and HindIII restriction enzymes). No colonies were expected on the Hygromycin plates 
additionally confirming that whatever is seen on the experiment plates was pTKL plasmid plus 
insert (Figure 5.17). 
 
Figure 5.17 Self-ligation controls showing that there was no self-ligation that occurred in the formation of both pTKL-
sRNA plasmids and pMV306-sRNA plasmids. A) pTKL plasmid linearized with HindIII restriction enzyme, B) pTKL 
plasmid linearized with both EcoRV and HindIII enzymes, C) pMV306 plasmid linearized with HindIII restriction 
enzyme, D) pMV306 plasmid linearized with both EcoRV and HindIII enzymes. 
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After confirming that the plasmids did not self-ligate we verified that the plasmids indeed 
ligated with the sRNAs and in order to do that we set up two experiments. The first experiment 
was PCR amplification with the respective sRNA primers. A positive amplification, as shown 
in Figure 5.18, indicated positive ligation of plasmid to sRNA fragment. The second 
verification experiment not only verified the presence of sRNA inserts but also the orientation 
to which they ligated to the plasmid. Figure 5.19 shows a diagrammatic presentation of the 
pTKL-sRNA plasmids as derived from the GENtle software 193. 
 
Figure 5.18 PCR and gel analysis to verify the presence of sRNA inserts in the pTKL plasmids. Positive PCR 
amplification of: A) mcr3 sRNA in pTKL-mcr3 plasmid, B) mpr6 sRNA in pTKL-mpr6 plasmid and C) ASpks sRNA 
in pTKL-ASpks plasmid. D) Restriction map obtained by digesting the pTKL-sRNA plasmids and controls: lane 1-3 is 
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the restriction map for pTKL-mcr3 plasmid, lane 4 and 5 is pTKL-ASpks plasmid, lane 6 and 7 – pTKL-mp6, lane 8 – 
wild-type pTKL plasmid and lane 9 – linearized pTKL plasmid. 
 
Figure 5.19 schematic representation of pTKL-sRNA plasmid generated using GENtle, A) pTKL, B) pTKL-mcr3, C) 
pTKL-mpr6, D) pTKL-ASpks. 
 
Constructs containing sRNA gene candidates were successfully created and the presence of 
inserts was confirmed with colony PCR and restriction enzyme analysis. Unfortunately, 
attempts to transform M. smegmatis cells with pTKL and its derivatives, using the same method 
as described above to transform pMV306 constructs into M. smegmatis, failed repeatedly. No 
growth on plates pTKL + insert plasmids were obtained, whereas growth was seen on positive 
controls (cells transformed with control plasmids). In an attempt to troubleshoot several 
alterations to the original protocol for transformations were done, but to no avail (Figure 5.20). 
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Figure 5.20 Growth of M. smegmatis. Growth not seen on plates containing and pTKL + sRNA plasmids (A = Mcr3, B 
= Mpr6, C = ASpks), but growth was seen on positive controls (D = wild type pMV306, E = wild type M. smegmatis, F 
= wild type pTKL). Square plates were used to ensure isolation of discrete colonies. 
 
Although the plasmids were constructed successfully, their presence somehow was lethal to 
the bacterium. This strategy with pTKL constructs was thus abandoned after few attempts. Due 
to lack of time, no further experiments were done to find conditions where transformed cells 
could be isolated. Future work could include optimisation of culture protocols, perhaps in the 
presence and absence of promoter induction/repression with anhydrous tetracycline 
5.4 EXPRESSION OF MCR3 AND ASPKS sRNAs IN M. TB EXPOSED TO SUB-
LETHAL CONCENTRATIONS OF KANAMYCIN OR OFLOXACIN 
The objective of this experiment was to observe if the sRNA could be used for quantitative 
PCR (qPCR). For this experiment we chose two sRNAs, mcr3 and ASpks, based on their 
association with genes previously published to be involved in drug resistant mechanisms. The 
mcr3 sRNA is located upstream (promoter region) of the M. tb rrs gene, known to be involved 
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in aminoglycoside synthesis 147. Kanamycin was chosen as the test drug for the mcr3 sRNA 
and Moxifloxacin was chosen for the ASpks sRNA.  
RNA was successfully extracted using the above modified protocol (Chapter 4) even though 
the quantity was low it was clean and intact, from both bacterial strains. The quality and 
quantity of the sRNAs was assessed using the Nanodrop 2000c (Nano Drop technologies, Inc., 
USA) to ensure the absence of contaminating reagents. However, when used in proper 
experiments, assessment of purity and quality should be done with better instrumentation. 
Table 5.5 shows the sRNA and the bigger RNA concentrations obtained in the drug exposure 
experiment for each drug (KAN- mcr3 and MOX-ASpks). 
Table 5.5 RNA concentration from the in vitro drug exposure experiments Concentration as determined by the 
Nanodrop 2000c software. 
 
Sample 
I.D 
KANAMYCIN  
Sample 
ID 
MOXIFLOXACIN 
CONC ng/µl CONC ng/µl 
sRNA bigger RNA sRNA bigger RNA 
A1 23.7 22.0 A0 7.0 20.0 
A2 18.8 19.6 A0.015 16.5 47.7 
A3 14.7 35.0 A0.03 38.1 28.7 
A4 77.1 25.4 A1 13.4 28.5 
      
B1 49.6 16.2 B0 98.6 22.8 
B2 6.8 17.9 B0.015 37.6 35.8 
B3 62.3 27.3 B0.03 8.0 46.8 
B4 66.1 35.1 B1 27.1 32.7 
      
C1 9.7 11.5 C0 27.7 17.5 
C2 8.9 19.2 C0.015 33.5 24.1 
C3 18.4 26.1 C0.03 36.6 44.1 
C4 16.4 30.5 C1 21.5 42.2 
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RNA concentrations appear to be low, but that can be optimised by adapting elution volumes 
when eluting nucleic acid from columns. Secondly, depending on your downstream 
application, the amount of input material should be optimised as well.  
 
Figure 5.21 A representation of amplification curves (A-standard curve, E-mcr3 and G-ASpks). B) Shows the dilution 
factors and standard curve, using gDNA and sigA, constructed from the respective amplification curves A) by the Bio-
Rad CFX96TM Real-Time System. Curves E and F represent mcr3 sRNA and G and H represent ASpks sRNA. 
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It is also noteworthy that biological replicates did not yield more or less the same yield, 
indicating that more optimisation is needed and perhaps more experience. Melting peak 
analysis for the qPCR products as analysed on the Bio-Rad equipment showed no primer 
dimers and each gene had a unique melting peak (Figure 5.21). The standard curve generated 
had a best-fit linear regression line with a slope value of 3.6, an efficiency of 89.4% and a 
goodness-of-fit value of R^2 0.999. 
We did not quantitate transcription levels of the candidates here, but rather used this exercise 
to demonstrate that good quality RNA was isolated and that it could be used to make cDNA. 
This method thus, with further optimisation could be used to prepare sRNAs for downstream 
technologies. 
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CHAPTER 6: DISCUSSION 
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Drug resistance in TB is a growing problem, with “totally drug resistant” M. tb strains reported 
worldwide 194–198. The biology of how resistance is initiated and regulated in M. tb is still poorly 
understood; therefore a lot still needs to be done to elucidate this phenomenon of drug 
resistance. There has been a recent increase in studies focused on identifying sRNAs in 
Mycobacterial species (and other bacteria), but so little has been done to attach functionality to 
these sRNAs. Putative associations of drug resistance and sRNA genes are appearing in the 
literature, including in M. tuberculosis.  Many drug-resistance associated gene functions in 
clinically significant bacteria are not well comprehended and perhaps sRNA putative 
regulatory functions, if identified, will help to diminish that knowledge gap.  
We have therefore attempted, for the first time, to investigate the physiological effect some 
sRNAs play in Mycobacterial species. In order to do this, we have combined basic 
bioinformatics analysis processes with wet bench experiments to identify sRNAs with potential 
roles in drug resistance mechanisms. 
Firstly, we used an in-house Python Script developed in our department (by Ruben van der 
Merwe - unpublished data) to screen for SNPs in regions with previously described sRNAs.  
We aimed to discern if suspected SNPs were present, which strains they were found in, and if 
it they were found solely in drug resistant isolates.  This analysis revealed that most isolates 
with SNPs in candidate sRNAs were from the Beijing genotype, which was dominant as 
compared to other genotypes. This genotype is the most successful genotype, originally 
identified in Asia 199, but has successfully established itself as the most frequent isolate found 
amongst TB-infections worldwide, including South Africa.  The observed predominance in our 
study set thus could therefore be an artefact of its predominance in infections in this country.  
The Beijing family indeed is wide spread and owing to its genetic homogeneity several studies 
have hypothesised that it possesses a selective advantage over other strains. A study in 2005 
showed that the percentage of the Beijing genotype increased with drug resistance as compared 
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to other strains contributing to 75% of the drug resistant strains as per their study in central 
Asia 200. In the Eastern Cape province of South Africa, a study, done by Marisa Klopper et al,  
in our group showed that MDR-TB strains were diverse but pre-XDR and XDR-TB patients 
showed a genetic background restricted to the Beijing genotype 198 
 . This adds more weight to the above hypothesis and also adds to hypothesise that Beijing 
strains more readily acquire drug resistance associated mutations than other strains and are 
capable of spreading extensively regardless of fitness costs associated with mutations. 
However a study in Sweden in 2010 contradicted this hypothesis as they showed that in their 
population there were no extensive outbreaks of this strain as compared to other strains 201. 
Based on previous studies it is clear that the strain family Beijing has a potential selective 
advantage over other strains and from our findings sRNAs might have a role in explaining this 
selective advantage. 
Of the 36 regions previously associated with drug resistance and/or drug resistance genes, 
SNPs were we identified found in 29 of these SNPs in regions in our genome bank, all in 
consisting of drug resistant isolates. How and if these SNPs contribute to drug resistance is still 
unclear.  These SNPs could play a role in drug resistance given that drug resistance arises from 
mutations in genes associated with drug action and therefore warranty further investigations. 
The largest frequency of SNPs between isolates were found in the sRNAs namely; mcr3 - in 
the promoter region of a known drug resistant gene rrs and ASpks a sRNA confined in the 
pks12 gene were found in most of the drug resistant isolates in our clinical isolate genome 
bank.  However, larger data sets need to be screened for statistical associations to be made.  
However, since these SNPs were only found in resistant isolates, it does suggest an association 
with resistance, as previously suggested. The frequency of these SNPs could translate to 
function; future studies would therefore include investigating whether these SNPs have an 
effect on gene/sRNA function using wet bench techniques.  Within the rrs gene, which is co-
transcribed with mcr3, are SNPs shown to be associated with drug resistance. It is thus possible 
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that mcr3 could play a role in aminoglycoside resistance. Although base changes in non-coding 
regions does not result in changes in encoded products, such as found with non-synonymous 
SNPs in genes, it is becoming increasingly clear that even synonymous SNPs might have 
functional consequences in organisms.  Could these include alterations in the way drug-
resistance genes are regulated?  It is with this in mind, and the need to fill this knowledge gap, 
that we selected three candidates for functional characterisations. These candidate sRNAs were 
selected based on their associated with known drug resistant genes and or pathways.  
In a bid to investigate the effect of sRNAs on the physiology of M. tb, we over-expressed 
candidate sRNAs (mcr3, ASpks and mpr6) using the expression vector pMV306 in M. 
smegmatis and observed its effect on growth and drug resistance profile. Although we did not 
check for expression of the cloned candidates in M. smegmatis, the difference in growth 
indicates that the presence of the extra copies had a detrimental phenotypical effect on the 
bacterium. There was an approximately 5 fold decrease in growth rate when comparing the 
sRNA-transformed cell mutants with the wild type M. smegmatis strain or the strain 
transformed with the control plasmid. These results show that these sRNAs have an effect on 
the physiology of mycobacteria. For mcr3 and ASpks it can be speculated that their targets 
would be the genes with which they are co-transcribed with, namely rrs and pks12 respectively. 
As for mpr6, its effect on physiology might be more significant as its genomic locus is between 
two interacting sigma factors which are important regulators of various characteristics of 
bacteria.  
Unfortunately, we failed to utilize the plasmid pTKL, where the sRNA targets were cloned 
directly after a controllable promoter. For these plasmids to be useful, it appears that one has 
to find conditions where even its transformation into mycobacteria is tightly controlled by 
conditions that enable growth and prevents the lethal phenotype observed in this study.  Thus 
controlled expression of the sRNAs in M. smegmatis using a modified plasmid containing the 
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Tet ON/OFF promoter expression system still has to be optimized. Controlled expression 
vectors give you the flexibility of controlling expression levels particularly for toxic candidates 
or when a gene is only required to be expressed at particular time points and/in response to 
particular stimuli. This is effective in the analysis of gene function and hence why it is 
important to make this optimisation.  
In terms of sRNA effect on drug resistance: due to time constraints we only investigated 
whether expressing the sRNAs would induce sensitivity of M. smegmatis to anti-TB drugs. No 
growth was observed in both liquid and solid media suggesting that over expressing the sRNAs 
potentially affect/induce sensitivity to drugs in in vitro cultures.  However, such studies need 
to be done under various conditions that more closely resemble in vivo conditions and not 
laboratory in vitro conditions. More still needs to be done before concluding the effect of 
sRNAs on drug resistance.  
Lastly, we devised a shorter protocol to isolate various RNA species from mycobacteria. This 
protocol yielded intact RNA, both bigger transcripts and the sRNAs, by using a combination 
of columns to separate the different RNAs and concentrate the sRNAs. This RNA was DNA 
free and cDNA was successfully made from it.  Unfortunately low yields were obtained.  
Therefore this approach is still limited by the amount of culture that maximally is allowed per 
flask in our biosafety laboratory.  In order to yield increased concentrations of sRNAs, one can 
look at combining extractions from cells cultured in individual flasks under identical 
conditions, and extracted at exact identical time-points. Due to low yields, the sRNAs could 
not be used to construct standard curves. An alternative for standard curves thus could be to 
use genomic DNA instead of the cDNA. 
Another problem that was encountered when attempting to quantitate sRNA expression with 
quantitative qPCR is the fact that no sRNA reference “genes” have been established yet. Other 
researchers published results using 16S mRNA or other mRNA species as reference genes.  No 
Stellenbosch University  https://scholar.sun.ac.za
       Page 106 
 
doubt though, that experimental error can occur as all methods separate the isolation of sRNAs 
and mRNA steps. Unfortunately one cannot spike sRNAs with RNA to generate internal 
standards, as sRNA species are mostly associated with mRNA transcripts, either before or after 
genes or in the middle of transcripts.   
More sensitive and accurate methods of quantification such as the Bio-Analyzer should be used 
instead of the Nanodrop only.  
Although the level of the sRNAs were too low to generate a proper standard curve with cDNA 
made from sRNAs, there was enough template to generate a signal for each species we 
assessed. Instead of using the sRNA-derived cDNA, we decided to use genomic DNA to 
prepare a standard curve for DNA extractions as the amount of cDNA did not yield enough 
signal with the higher dilutions, thus yield is a problem.  Various dilution ranges were tested 
to find a set of concentrations that would accommodate Ct values obtained from sRNA derived-
cDNA. 
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With the growing problem of drug resistant TB it is paramount that new therapies evolve to 
combat new M. tb strains. From the discovery of the first TB drugs to date there has been a few 
new drugs added to TB treatment regimens. Partly this is a result of the lack of a comprehensive 
understanding of how M. tb metabolic functions occur.  
Small RNA studies could shed light as to how regulatory mechanisms in mycobacteria occur 
filling a big part in the current knowledge gap. They could provide new drug targets turning 
drug resistant strains into sensitive strains and help treat patients regarded as therapeutically 
destitute. The field of sRNAs is new and hence more still needs to be done such as optimising 
protocols for some of the most used techniques such as qPCR and cloning.  
This study has confirmed the presence of previous identified SNPs in sRNAs of drug resistant 
isolates.  We also have shown that the sRNAs investigated here have an effect on the 
physiology of mycobacteria, both in the presence and absence of antibiotics, although more in-
depth studies need to be performed to confirm these observations.  Most importantly, we 
designed a protocol to isolate sRNAs successfully using commercial kits.  Future studies 
include further optimisation of this protocols for use with sRNAs in order to increase yield.  
The limitations of the study included the lack of sRNA reference genes for qPCR; because 
sRNAs are associated with mRNA transcripts and given that their target mRNAs are still 
unknown current reference genes are not suitable for qPCR. The lack of understanding of how 
sRNAs are transcribed and post transcriptionally modified made it difficult to design proper 
cloning strategies. Therefore in future actually investigating to see if a particular sRNA is 
transcribed instead of assuming it is based on a change of phenotype would be paramount in 
elucidating function of sRNAs. Generally sRNAs constitute a small percentage of the total 
RNA therefore proper extraction methods are required that utilise less harsh chemicals like 
phenol and have very few steps at which RNA can be lost or contaminated. The method we 
designed is promising in the sense that it eliminates unnecessary steps and chemicals that lead 
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to the loss of RNA although it still needs to be improved in terms of consistency as one can 
notice the wide ranges of the RNA concentration. Although the quantity was low the quality 
was good, one can work around the low quantity issue by increasing the amount of starter 
culture. And because of this low quantity of sRNAs a standard curve using the sRNAs could 
not be created but we showed that one can use genomic DNA to create a standard curve. It is 
unfortunate that although we were successful in creating a controllable plasmid (pTKL) with 
the derivative sRNAs we could not successfully transform M. smegmatis; in our future studies 
we aim to optimise transformation by changing the reaction conditions etc. 
Overall, future studies will be to understand the role of sRNAs in mycobacterial virulence and 
drug resistance. Also we would like to optimise major molecular biology processes like 
cloning, qPCR etc., and also identify more sRNAs that have any association with drug resistant 
pathways.  
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APPENDICES 
 
APPENDIX 1 - Protocols 
1. Plasmid pTKL construction 
Protocol A 
1. Dephosphorylation of pSE100 fragment ( company name) 
- 7µl H2O, 10µl pSE100 fragment, 2µl Phosphatase Buffer and 1µl Phosphatase  
- Incubate at 37˚C for 10min, inactivate enzyme at 75˚C for 2min and chill on ice for 
2min 
2. Ligation of the pMV306 fragment to the dephosphorylated (dephos) pSE100 fragment 
- 4µl of the dephos pSE100, 5µl pMV306 fragment, 10µl 2X ligation buffer (Thermo 
Scientific) and 1µl T4 DNA ligase (Thermo Scientific). 
- Incubate at 22˚C or room temperature (RTM) for 20min. 
3. Clean up 
- Clean up the reaction from 2 with the Zymoclean Gel clean-up kit (contains a DNA 
binding buffer that can be used to clean up DNA from contaminating reagents. 
4. Blunting of the pSE100 end cut with ClaI 
- 8µl pSE100-pMV306 fragment, 10µl 2X reaction buffer (Thermo Scientific) and 1µl 
Blunting enzyme (Thermo Scientific). 
- Incubate at 70˚C for 5min and chill on ice for 2min. 
5. Final Ligation ( circularizing the plasmid) and transformation 
- Add 1µl T4 DNA ligase to the reaction mixture from (4). 
- Incubate at 22˚C or room temperature (RTM) for 20min. 
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- Use the whole mixture (20µl) to transform 200 µl of chemical competent E.coli cells 
(protocol in appendix--). 
- Plate on LB agar hygromycin plates and incubate over night at 37˚C 
Protocol B 
1. Blunting of pSE100 fragment 
- 9µl pMV306 fragment, 10µl 2X reaction buffer (Thermo Scientific) and 1µl Blunting 
enzyme (Thermo Scientific). 
- Incubate at 70˚C for 5min and chill on ice for 2min. 
2. Clean up 
- Clean up the reaction from 1 with the Zymoclean Gel clean-up kit (contains a DNA 
binding buffer that can be used to clean up DNA from contaminating reagents. 
3. Dephosphorylation of pSE100 blunted fragment ( company name) 
- 17µl dephos pSE100 fragment, 2µl Phosphatase Buffer and 1µl Phosphatase  
- Incubate at 37˚C for 10min, inactivate enzyme at 75˚C for 2min and chill on ice for 
2min 
4. Ligation of the pMV306 fragment to the dephosphorylated (dephos) pSE100 fragment 
- Add 1µl T4 DNA ligase to the reaction mixture from (4). 
- Incubate at 22˚C or room temperature (RTM) for 20min. 
Use the whole mixture (20µl) to transform 200 µl of chemical competent E.coli cells (protocol 
in appendix--). 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
       Page 112 
 
BIBLIOGRAPHY 
 
1. Global tuberculosis control - epidemiology, strategy, financing, WHO. WHO | Global 
tuberculosis control - epidemiology, strategy, financing. WHO (2009). at 
<http://www.who.int/tb/publications/global_report/2009/en/index.html> 
2. TB Online. TB Online - South Africa: Infectious XDR-TB patients being sent home. 
(2014). at <http://www.tbonline.info/posts/2014/4/7/south-africa-infectious-xdr-tb-
patients-being-sent/> 
3. CDC | TB | Drug-Resistant TB. CDC | TB | Drug-Resistant TB. (2015). at 
<http://www.cdc.gov/tb/topic/drtb/> 
4. Storz, G., Vogel, J. & Wassarman, K. M. Regulation by small RNAs in bacteria: 
expanding frontiers. Mol. Cell 43, 880–891 (2011). 
5. Gottesman, S. Micros for microbes: non-coding regulatory RNAs in bacteria. Trends 
Genet. TIG 21, 399–404 (2005). 
6. Lee, R. C., Feinbaum, R. L. & Ambros, V. The C. elegans heterochronic gene lin-4 
encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843–854 
(1993). 
7. Ambros, V. The functions of animal microRNAs. Nature 431, 350–355 (2004). 
8. Chen, K. & Rajewsky, N. The evolution of gene regulation by transcription factors and 
microRNAs. Nat. Rev. Genet. 8, 93–103 (2007). 
9. Tjaden, B. et al. Target prediction for small, noncoding RNAs in bacteria. Nucleic Acids 
Res. 34, 2791–2802 (2006). 
10. Wassarman, K. M., Repoila, F., Rosenow, C., Storz, G. & Gottesman, S. Identification 
of novel small RNAs using comparative genomics and microarrays. Genes Dev. 15, 
1637–1651 (2001). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 113 
 
11. Gottesman, S. The small RNA regulators of Escherichia coli: roles and mechanisms*. 
Annu. Rev. Microbiol. 58, 303–328 (2004). 
12. Stougaard, P., Molin, S. & Nordström, K. RNAs involved in copy-number control and 
incompatibility of plasmid R1. Proc. Natl. Acad. Sci. U. S. A. 78, 6008–6012 (1981). 
13. Tomizawa, J., Itoh, T., Selzer, G. & Som, T. Inhibition of ColE1 RNA primer formation 
by a plasmid-specified small RNA. Proc. Natl. Acad. Sci. U. S. A. 78, 1421–1425 
(1981). 
14. Simons, R. W. & Kleckner, N. Translational control of IS10 transposition. Cell 34, 683–
691 (1983). 
15. Mizuno, T., Chou, M. Y. & Inouye, M. A unique mechanism regulating gene 
expression: translational inhibition by a complementary RNA transcript (micRNA). 
Proc. Natl. Acad. Sci. 81, 1966–1970 (1984). 
16. Hershberg, R., Altuvia, S. & Margalit, H. A survey of small RNA‐encoding genes in 
Escherichia coli. Nucleic Acids Res. 31, 1813–1820 (2003). 
17. Romby, P., Vandenesch, F. & Wagner, E. G. H. The role of RNAs in the regulation of 
virulence-gene expression. Curr. Opin. Microbiol. 9, 229–236 (2006). 
18. Altier, C., Suyemoto, M., Ruiz, A. I., Burnham, K. D. & Maurer, R. Characterization of 
two novel regulatory genes affecting Salmonella invasion gene expression. Mol. 
Microbiol. 35, 635–646 (2000). 
19. Figueroa-Bossi, N., Valentini, M., Malleret, L., Fiorini, F. & Bossi, L. Caught at its own 
game: regulatory small RNA inactivated by an inducible transcript mimicking its target. 
Genes Dev. 23, 2004–2015 (2009). 
20. Iyer, V. R., Sharma, R., Pathania, R. & Navani, N. K. Small RNAs of Pathogenic 
Bacteria: Not Small Enough to be Overlooked for Therapeutics. Mol. Cell. Pharmacol. 
4, 17–30 (2012). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 114 
 
21. Lenz, D. H. et al. The small RNA chaperone Hfq and multiple small RNAs control 
quorum sensing in Vibrio harveyi and Vibrio cholerae. Cell 118, 69–82 (2004). 
22. Lenz, D. H., Miller, M. B., Zhu, J., Kulkarni, R. V. & Bassler, B. L. CsrA and three 
redundant small RNAs regulate quorum sensing in Vibrio cholerae. Mol. Microbiol. 58, 
1186–1202 (2005). 
23. Mraheil, M. A. et al. The intracellular sRNA transcriptome of Listeria monocytogenes 
during growth in macrophages. Nucleic Acids Res. 39, 4235–4248 (2011). 
24. Schilling, D., Findeiss, S., Richter, A. S., Taylor, J. A. & Gerischer, U. The small RNA 
Aar in Acinetobacter baylyi: a putative regulator of amino acid metabolism. Arch. 
Microbiol. 192, 691–702 (2010). 
25. Wilderman, P. J. et al. Identification of tandem duplicate regulatory small RNAs in 
Pseudomonas aeruginosa involved in iron homeostasis. Proc. Natl. Acad. Sci. U. S. A. 
101, 9792–9797 (2004). 
26. Altuvia, S. Identification of bacterial small non-coding RNAs: experimental approaches. 
Curr. Opin. Microbiol. 10, 257–261 (2007). 
27. Billoud, B., Kontic, M. & Viari, A. Palingol: a declarative programming language to 
describe nucleic acids’ secondary structures and to scan sequence database. Nucleic 
Acids Res. 24, 1395–1403 (1996). 
28. Chen, S. et al. A bioinformatics based approach to discover small RNA genes in the 
Escherichia coli genome. Biosystems 65, 157–177 (2002). 
29. Delihas, N. Annotation and evolutionary relationships of a small regulatory RNA gene 
micF and its target ompF in Yersinia species. BMC Microbiol. 3, 13 (2003). 
30. Carter, R. J., Dubchak, I. & Holbrook, S. R. A computational approach to identify genes 
for functional RNAs in genomic sequences. Nucleic Acids Res. 29, 3928–3938 (2001). 
31. Salari, R. et al. smyRNA: a novel Ab initio ncRNA gene finder. PloS One 4, e5433 
(2009). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 115 
 
32. Salzberg, S. L., Delcher, A. L., Kasif, S. & White, O. Microbial gene identification 
using interpolated Markov models. Nucleic Acids Res. 26, 544–548 (1998). 
33. Delcher, A. L., Harmon, D., Kasif, S., White, O. & Salzberg, S. L. Improved microbial 
gene identification with GLIMMER. Nucleic Acids Res. 27, 4636–4641 (1999). 
34. Delcher, A. L., Bratke, K. A., Powers, E. C. & Salzberg, S. L. Identifying bacterial 
genes and endosymbiont DNA with Glimmer. Bioinforma. Oxf. Engl. 23, 673–679 
(2007). 
35. Lukashin, A. V. & Borodovsky, M. GeneMark.hmm: new solutions for gene finding. 
Nucleic Acids Res. 26, 1107–1115 (1998). 
36. Besemer, J. & Borodovsky, M. Heuristic approach to deriving models for gene finding. 
Nucleic Acids Res. 27, 3911–3920 (1999). 
37. Besemer, J., Lomsadze, A. & Borodovsky, M. GeneMarkS: a self-training method for 
prediction of gene starts in microbial genomes. Implications for finding sequence motifs 
in regulatory regions. Nucleic Acids Res. 29, 2607–2618 (2001). 
38. Lee, Y. et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425, 
415–419 (2003). 
39. Han, J. et al. Molecular basis for the recognition of primary microRNAs by the Drosha-
DGCR8 complex. Cell 125, 887–901 (2006). 
40. Kim, V. N., Han, J. & Siomi, M. C. Biogenesis of small RNAs in animals. Nat. Rev. 
Mol. Cell Biol. 10, 126–139 (2009). 
41. Chekulaeva, M. & Filipowicz, W. Mechanisms of miRNA-mediated post-transcriptional 
regulation in animal cells. Curr. Opin. Cell Biol. 21, 452–460 (2009). 
42. Arnvig, K. B. et al. Sequence-based analysis uncovers an abundance of non-coding 
RNA in the total transcriptome of Mycobacterium tuberculosis. PLoS Pathog. 7, 
e1002342 (2011). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 116 
 
43. Arnvig, K. & Young, D. Non-coding RNA and its potential role in Mycobacterium 
tuberculosis pathogenesis. RNA Biol. 9, 427–436 (2012). 
44. Waters, L. S. & Storz, G. Regulatory RNAs in bacteria. Cell 136, 615–628 (2009). 
45. Brantl, S. Regulatory mechanisms employed by cis-encoded antisense RNAs. Curr. 
Opin. Microbiol. 10, 102–109 (2007). 
46. Schumacher, M. A., Pearson, R. F., Møller, T., Valentin-Hansen, P. & Brennan, R. G. 
Structures of the pleiotropic translational regulator Hfq and an Hfq-RNA complex: a 
bacterial Sm-like protein. EMBO J. 21, 3546–3556 (2002). 
47. Picard, F., Dressaire, C., Girbal, L. & Cocaign-Bousquet, M. Examination of post-
transcriptional regulations in prokaryotes by integrative biology. C. R. Biol. 332, 958–
973 (2009). 
48. Sobrero, P. & Valverde, C. The bacterial protein Hfq: much more than a mere RNA-
binding factor. Crit. Rev. Microbiol. 38, 276–299 (2012). 
49. Arluison, V. et al. Spectroscopic observation of RNA chaperone activities of Hfq in 
post-transcriptional regulation by a small non-coding RNA. Nucleic Acids Res. 35, 999–
1006 (2007). 
50. Li, S.-K. et al. Identification of small RNAs in Mycobacterium smegmatis using 
heterologous Hfq. RNA 19, 74–84 (2013). 
51. Storz, G., Vogel, J. & Wassarman, K. M. Regulation by small RNAs in bacteria: 
expanding frontiers. Mol. Cell 43, 880–891 (2011). 
52. Man, S. et al. Artificial trans-encoded small non-coding RNAs specifically silence the 
selected gene expression in bacteria. Nucleic Acids Res. (2011). doi:10.1093/nar/gkr034 
53. Folichon, M. The poly(A) binding protein Hfq protects RNA from RNase E and 
exoribonucleolytic degradation. Nucleic Acids Res. 31, 7302–7310 (2003). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 117 
 
54. Henderson, C. A. et al. Hfq binding changes the structure of Escherichia coli small 
noncoding RNAs OxyS and RprA, which are involved in the riboregulation of rpoS. 
RNA 19, 1089–1104 (2013). 
55. Arluison, V. et al. Three-dimensional Structures of Fibrillar Sm Proteins: Hfq and Other 
Sm-like Proteins. J. Mol. Biol. 356, 86–96 (2006). 
56. Geissmann, T. A. & Touati, D. Hfq, a new chaperoning role: binding to messenger RNA 
determines access for small RNA regulator. EMBO J. 23, 396–405 (2004). 
57. Mohanty, B. K., Maples, V. F. & Kushner, S. R. The Sm-like protein Hfq regulates 
polyadenylation dependent mRNA decay in Escherichia coli. Mol. Microbiol. 54, 905–
920 (2004). 
58. Moll, I., Afonyushkin, T., Vytvytska, O., Kaberdin, V. R. & Bläsi, U. Coincident Hfq 
binding and RNase E cleavage sites on mRNA and small regulatory RNAs. RNA N. Y. N 
9, 1308–1314 (2003). 
59. Jousselin, A., Metzinger, L. & Felden, B. On the facultative requirement of the bacterial 
RNA chaperone, Hfq. Trends Microbiol. 17, 399–405 (2009). 
60. Nielsen, J. S. et al. Defining a role for Hfq in Gram-positive bacteria: evidence for Hfq-
dependent antisense regulation in Listeria monocytogenes. Nucleic Acids Res. 38, 907–
919 (2010). 
61. Sonnleitner, E. et al. Reduced virulence of a hfq mutant of Pseudomonas aeruginosa O1. 
Microb. Pathog. 35, 217–228 (2003). 
62. Chiang, M.-K., Lu, M.-C., Liu, L.-C., Lin, C.-T. & Lai, Y.-C. Impact of Hfq on Global 
Gene Expression and Virulence in Klebsiella pneumoniae. PLoS ONE 6, e22248 (2011). 
63. Guisbert, E., Rhodius, V. A., Ahuja, N., Witkin, E. & Gross, C. A. Hfq Modulates the 
σE-Mediated Envelope Stress Response and the σ32-Mediated Cytoplasmic Stress 
Response in Escherichia coli. J. Bacteriol. 189, 1963–1973 (2007). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 118 
 
64. Blumenthal, T. & Carmichael, G. G. RNA replication: function and structure of Qbeta-
replicase. Annu. Rev. Biochem. 48, 525–548 (1979). 
65. Kidmose, R. T., Vasiliev, N. N., Chetverin, A. B., Andersen, G. R. & Knudsen, C. R. 
Structure of the Qβ replicase, an RNA-dependent RNA polymerase consisting of viral 
and host proteins. Proc. Natl. Acad. Sci. U. S. A. 107, 10884–10889 (2010). 
66. Arnvig, K. B. & Young, D. B. Identification of small RNAs in Mycobacterium 
tuberculosis. Mol. Microbiol. 73, 397–408 (2009). 
67. Thomason, M. K. & Storz, G. Bacterial antisense RNAs: How many are there and what 
are they doing? Annu. Rev. Genet. 44, 167–188 (2010). 
68. Faubladier, M. & Bouché, J. P. Division inhibition gene dicF of Escherichia coli reveals 
a widespread group of prophage sequences in bacterial genomes. J. Bacteriol. 176, 
1150–1156 (1994). 
69. Cayrol, B. et al. Auto-assembly of E. coli DsrA small noncoding RNA: Molecular 
characteristics and functional consequences. RNA Biol. 6, 434–445 (2009). 
70. Urban, J. H. & Vogel, J. Translational control and target recognition by Escherichia coli 
small RNAs in vivo. Nucleic Acids Res. 35, 1018–1037 (2007). 
71. Lease, R. A. & Belfort, M. A trans-acting RNA as a control switch in Escherichia coli: 
DsrA modulates function by forming alternative structures. Proc. Natl. Acad. Sci. U. S. 
A. 97, 9919–9924 (2000). 
72. Majdalani, N., Cunning, C., Sledjeski, D., Elliott, T. & Gottesman, S. DsrA RNA 
regulates translation of RpoS message by an anti-antisense mechanism, independent of 
its action as an antisilencer of transcription. Proc. Natl. Acad. Sci. U. S. A. 95, 12462–
12467 (1998). 
73. Sledjeski, D. D., Whitman, C. & Zhang, A. Hfq is necessary for regulation by the 
untranslated RNA DsrA. J. Bacteriol. 183, 1997–2005 (2001). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 119 
 
74. Poole, R. K., Gibson, F. & Wu, G. The cydD gene product, component of a 
heterodimeric ABC transporter, is required for assembly of periplasmic cytochrome c 
and of cytochrome bd in Escherichia coli. FEMS Microbiol. Lett. 117, 217–223 (1994). 
75. Boysen, A., Møller-Jensen, J., Kallipolitis, B., Valentin-Hansen, P. & Overgaard, M. 
Translational regulation of gene expression by an anaerobically induced small non-
coding RNA in Escherichia coli. J. Biol. Chem. 285, 10690–10702 (2010). 
76. Opdyke, J. A., Kang, J.-G. & Storz, G. GadY, a small-RNA regulator of acid response 
genes in Escherichia coli. J. Bacteriol. 186, 6698–6705 (2004). 
77. Urbanowski, M. L., Stauffer, L. T. & Stauffer, G. V. The gcvB gene encodes a small 
untranslated RNA involved in expression of the dipeptide and oligopeptide transport 
systems in Escherichia coli. Mol. Microbiol. 37, 856–868 (2000). 
78. Pulvermacher, S. C., Stauffer, L. T. & Stauffer, G. V. Role of the Escherichia coli Hfq 
protein in GcvB regulation of oppA and dppA mRNAs. Microbiol. Read. Engl. 155, 
115–123 (2009). 
79. Sharma, C. M., Darfeuille, F., Plantinga, T. H. & Vogel, J. A small RNA regulates 
multiple ABC transporter mRNAs by targeting C/A-rich elements inside and upstream 
of ribosome-binding sites. Genes Dev. 21, 2804–2817 (2007). 
80. Pulvermacher, S. C., Stauffer, L. T. & Stauffer, G. V. The small RNA GcvB regulates 
sstT mRNA expression in Escherichia coli. J. Bacteriol. 191, 238–248 (2009). 
81. Pulvermacher, S. C., Stauffer, L. T. & Stauffer, G. V. Role of the sRNA GcvB in 
regulation of cycA in Escherichia coli. Microbiol. Read. Engl. 155, 106–114 (2009). 
82. Padalon-Brauch, G. et al. Small RNAs encoded within genetic islands of Salmonella 
typhimurium show host-induced expression and role in virulence. Nucleic Acids Res. 36, 
1913–1927 (2008). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 120 
 
83. Rasmussen, A. A. et al. Regulation of ompA mRNA stability: the role of a small 
regulatory RNA in growth phase-dependent control. Mol. Microbiol. 58, 1421–1429 
(2005). 
84. Udekwu, K. I. et al. Hfq-dependent regulation of OmpA synthesis is mediated by an 
antisense RNA. Genes Dev. 19, 2355–2366 (2005). 
85. Chen, S., Zhang, A., Blyn, L. B. & Storz, G. MicC, a second small-RNA regulator of 
Omp protein expression in Escherichia coli. J. Bacteriol. 186, 6689–6697 (2004). 
86. Delihas, N. & Forst, S. MicF: an antisense RNA gene involved in response of 
Escherichia coli to global stress factors. J. Mol. Biol. 313, 1–12 (2001). 
87. Guillier, M. & Gottesman, S. Remodelling of the Escherichia coli outer membrane by 
two small regulatory RNAs. Mol. Microbiol. 59, 231–247 (2006). 
88. Guillier, M. & Gottesman, S. The 5’ end of two redundant sRNAs is involved in the 
regulation of multiple targets, including their own regulator. Nucleic Acids Res. 36, 
6781–6794 (2008). 
89. Holmqvist, E. et al. Two antisense RNAs target the transcriptional regulator CsgD to 
inhibit curli synthesis. EMBO J. 29, 1840–1850 (2010). 
90. Altuvia, S., Zhang, A., Argaman, L., Tiwari, A. & Storz, G. The Escherichia coli OxyS 
regulatory RNA represses fhlA translation by blocking ribosome binding. EMBO J. 17, 
6069–6075 (1998). 
91. Svenningsen, S. L., Tu, K. C. & Bassler, B. L. Gene dosage compensation calibrates 
four regulatory RNAs to control Vibrio cholerae quorum sensing. EMBO J. 28, 429–439 
(2009). 
92. Tu, K. C., Waters, C. M., Svenningsen, S. L. & Bassler, B. L. A small-RNA-mediated 
negative feedback loop controls quorum-sensing dynamics in Vibrio harveyi. Mol. 
Microbiol. 70, 896–907 (2008). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 121 
 
93. Updegrove, T., Wilf, N., Sun, X. & Wartell, R. M. Effect of Hfq on RprA-rpoS mRNA 
pairing: Hfq-RNA binding and the influence of the 5’ rpoS mRNA leader region. 
Biochemistry (Mosc.) 47, 11184–11195 (2008). 
94. Jones, A. M., Goodwill, A. & Elliott, T. Limited role for the DsrA and RprA regulatory 
RNAs in rpoS regulation in Salmonella enterica. J. Bacteriol. 188, 5077–5088 (2006). 
95. Mika, F. et al. Targeting of csgD by the small regulatory RNA RprA links stationary 
phase, biofilm formation and cell envelope stress in Escherichia coli. Mol. Microbiol. 
84, 51–65 (2012). 
96. Papenfort, K. et al. SigmaE-dependent small RNAs of Salmonella respond to membrane 
stress by accelerating global omp mRNA decay. Mol. Microbiol. 62, 1674–1688 (2006). 
97. Antal, M., Bordeau, V., Douchin, V. & Felden, B. A small bacterial RNA regulates a 
putative ABC transporter. J. Biol. Chem. 280, 7901–7908 (2005). 
98. Argaman, L. et al. Novel small RNA-encoding genes in the intergenic regions of 
Escherichia coli. Curr. Biol. CB 11, 941–950 (2001). 
99. Papenfort, K. et al. Systematic deletion of Salmonella small RNA genes identifies 
CyaR, a conserved CRP-dependent riboregulator of OmpX synthesis. Mol. Microbiol. 
68, 890–906 (2008). 
100. Massé, E. & Gottesman, S. A small RNA regulates the expression of genes involved in 
iron metabolism in Escherichia coli. Proc. Natl. Acad. Sci. 99, 4620–4625 (2002). 
101. Vanderpool, C. K. & Gottesman, S. The novel transcription factor SgrR coordinates the 
response to glucose-phosphate stress. J. Bacteriol. 189, 2238–2248 (2007). 
102. Rice, J. B. & Vanderpool, C. K. The small RNA SgrS controls sugar-phosphate 
accumulation by regulating multiple PTS genes. Nucleic Acids Res. 39, 3806–3819 
(2011). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 122 
 
103. Kawamoto, H., Koide, Y., Morita, T. & Aiba, H. Base-pairing requirement for RNA 
silencing by a bacterial small RNA and acceleration of duplex formation by Hfq. Mol. 
Microbiol. 61, 1013–1022 (2006). 
104. Maki, K., Morita, T., Otaka, H. & Aiba, H. A minimal base-pairing region of a bacterial 
small RNA SgrS required for translational repression of ptsG mRNA. Mol. Microbiol. 
76, 782–792 (2010). 
105. Møller, T., Franch, T., Udesen, C., Gerdes, K. & Valentin-Hansen, P. Spot 42 RNA 
mediates discoordinate expression of the E. coli galactose operon. Genes Dev. 16, 1696–
1706 (2002). 
106. Polayes, D. A., Rice, P. W. & Dahlberg, J. E. DNA polymerase I activity in Escherichia 
coli is influenced by spot 42 RNA. J. Bacteriol. 170, 2083–2088 (1988). 
107. Papenfort, K. et al. Specific and pleiotropic patterns of mRNA regulation by ArcZ, a 
conserved, Hfq-dependent small RNA. Mol. Microbiol. 74, 139–158 (2009). 
108. Mandin, P. & Gottesman, S. Integrating anaerobic/aerobic sensing and the general stress 
response through the ArcZ small RNA. EMBO J. 29, 3094–3107 (2010). 
109. Kalamorz, F., Reichenbach, B., März, W., Rak, B. & Görke, B. Feedback control of 
glucosamine-6-phosphate synthase GlmS expression depends on the small RNA GlmZ 
and involves the novel protein YhbJ in Escherichia coli. Mol. Microbiol. 65, 1518–1533 
(2007). 
110. Urban, J. H., Papenfort, K., Thomsen, J., Schmitz, R. A. & Vogel, J. A conserved small 
RNA promotes discoordinate expression of the glmUS operon mRNA to activate GlmS 
synthesis. J. Mol. Biol. 373, 521–528 (2007). 
111. Reichenbach, B., Maes, A., Kalamorz, F., Hajnsdorf, E. & Görke, B. The small RNA 
GlmY acts upstream of the sRNA GlmZ in the activation of glmS expression and is 
subject to regulation by polyadenylation in Escherichia coli. Nucleic Acids Res. 36, 
2570–2580 (2008). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 123 
 
112. Urban, J. H. & Vogel, J. Two seemingly homologous noncoding RNAs act 
hierarchically to activate glmS mRNA translation. PLoS Biol. 6, e64 (2008). 
113. Rasmussen, A. A. et al. A conserved small RNA promotes silencing of the outer 
membrane protein YbfM. Mol. Microbiol. 72, 566–577 (2009). 
114. Mandin, P. & Gottesman, S. A genetic approach for finding small RNAs regulators of 
genes of interest identifies RybC as regulating the DpiA/DpiB two-component system. 
Mol. Microbiol. 72, 551–565 (2009). 
115. Vogel, J. et al. RNomics in Escherichia coli detects new sRNA species and indicates 
parallel transcriptional output in bacteria. Nucleic Acids Res. 31, 6435–6443 (2003). 
116. Jain, C. Identification and Characterization of Growth Suppressors of Escherichia coli 
Strains Lacking Phosphorolytic Ribonucleases. J. Bacteriol. 191, 5622–5627 (2009). 
117. Akey, D. L. & Berger, J. M. Structure of the nuclease domain of ribonuclease III from 
M. tuberculosis at 2.1 ? Protein Sci. Publ. Protein Soc. 14, 2744–2750 (2005). 
118. Kovacs, L., Csanadi, A., Megyeri, K., Kaberdin, V. R. & Miczak, A. Mycobacterial 
RNase E-Associated Proteins. Microbiol. Immunol. 49, 1003–1007 (2005). 
119. Rustad, T. R. et al. Global analysis of mRNA stability in Mycobacterium tuberculosis. 
Nucleic Acids Res. gks1019 (2012). doi:10.1093/nar/gks1019 
120. Bandyra, K. J. et al. The Seed Region of a Small RNA Drives the Controlled 
Destruction of the Target mRNA by the Endoribonuclease RNase E. Mol. Cell 47, 943–
953 (2012). 
121. Csanadi, A. et al. Towards new antituberculotic targets: biochemical characterisation of 
mycobacterial RNase E/G. Eur. Respir. Rev. 17, 76–77 (2008). 
122. Majdalani, N., Vanderpool, C. K. & Gottesman, S. Bacterial small RNA regulators. 
Crit. Rev. Biochem. Mol. Biol. 40, 93–113 (2005). 
123. Waters, L. S. & Storz, G. Regulatory RNAs in bacteria. Cell 136, 615–628 (2009). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 124 
 
124. Brown, L. & Elliott, T. Mutations that increase expression of the rpoS gene and 
decrease its dependence on hfq function in Salmonella typhimurium. J. Bacteriol. 179, 
656–662 (1997). 
125. Zhang, A., Wassarman, K. M., Ortega, J., Steven, A. C. & Storz, G. The Sm-like Hfq 
Protein Increases OxyS RNA Interaction with Target mRNAs. Mol. Cell 9, 11–22 
(2002). 
126. McHugh, J. P. et al. Global iron-dependent gene regulation in Escherichia coli. A new 
mechanism for iron homeostasis. J. Biol. Chem. 278, 29478–29486 (2003). 
127. Massé, E., Escorcia, F. E. & Gottesman, S. Coupled degradation of a small regulatory 
RNA and its mRNA targets in Escherichia coli. Genes Dev. 17, 2374–2383 (2003). 
128. Calvori, C., Frontali, L., Leoni, L. & Tecce, G. Effect of rifamycin on protein synthesis. 
Nature 207, 417–418 (1965). 
129. Bohn, C., Rigoulay, C. & Bouloc, P. No detectable effect of RNA-binding protein Hfq 
absence in Staphylococcus aureus. BMC Microbiol. 7, 10 (2007). 
130. Novick, R. P. et al. Synthesis of staphylococcal virulence factors is controlled by a 
regulatory RNA molecule. EMBO J. 12, 3967–3975 (1993). 
131. Bhakdi, S. & Tranum-Jensen, J. Alpha-toxin of Staphylococcus aureus. Microbiol. Rev. 
55, 733–751 (1991). 
132. Graille, M. et al. Crystal structure of a Staphylococcus aureus protein A domain 
complexed with the Fab fragment of a human IgM antibody: Structural basis for 
recognition of B-cell receptors and superantigen activity. Proc. Natl. Acad. Sci. 97, 
5399–5404 (2000). 
133. Huntzinger, E. et al. Staphylococcus aureus RNAIII and the endoribonuclease III 
coordinately regulate spa gene expression. EMBO J. 24, 824–835 (2005). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 125 
 
134. Geisinger, E., Adhikari, R. P., Jin, R., Ross, H. F. & Novick, R. P. Inhibition of rot 
translation by RNAIII, a key feature of agr function. Mol. Microbiol. 61, 1038–1048 
(2006). 
135. Majdalani, N., Vanderpool, C. K. & Gottesman, S. Bacterial small RNA regulators. 
Crit. Rev. Biochem. Mol. Biol. 40, 93–113 (2005). 
136. Ramos, C. G., da Costa, P. J. P., Döring, G. & Leitão, J. H. The Novel Cis-Encoded 
Small RNA h2cR Is a Negative Regulator of hfq2 in Burkholderia cenocepacia. PLoS 
ONE 7, e47896 (2012). 
137. DiChiara, J. M. et al. Multiple small RNAs identified in Mycobacterium bovis BCG are 
also expressed in Mycobacterium tuberculosis and Mycobacterium smegmatis. Nucleic 
Acids Res. 38, 4067–4078 (2010). 
138. Miotto, P. et al. Genome-Wide Discovery of Small RNAs in Mycobacterium 
tuberculosis. PLoS ONE 7, e51950 (2012). 
139. Pellin, D., Miotto, P., Ambrosi, A., Cirillo, D. M. & Di Serio, C. A Genome-Wide 
Identification Analysis of Small Regulatory RNAs in Mycobacterium tuberculosis by 
RNA-Seq and Conservation Analysis. PLoS ONE 7, e32723 (2012). 
140. Tsai, C.-H. et al. Identification of Novel sRNAs in Mycobacterial Species. PLoS ONE 
8, e79411 (2013). 
141. Gandhi, N. R. et al. Extensively drug-resistant tuberculosis as a cause of death in 
patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 
368, 1575–1580 (2006). 
142. Gandhi, N. R. et al. Risk factors for mortality among MDR- and XDR-TB patients in a 
high HIV prevalence setting. Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung 
Dis. 16, 90–97 (2012). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 126 
 
143. Zhang, H. et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from 
China identifies genes and intergenic regions associated with drug resistance. Nat. 
Genet. 45, 1255–1260 (2013). 
144. Yu, J. & Schneiders, T. Tigecycline challenge triggers sRNA production in Salmonella 
enterica serovar Typhimurium. BMC Microbiol. 12, 1–13 (2012). 
145. Howden, B. P. et al. Analysis of the small RNA transcriptional response in multidrug-
resistant Staphylococcus aureus after antimicrobial exposure. Antimicrob. Agents 
Chemother. 57, 3864–3874 (2013). 
146. Eyraud, A., Tattevin, P., Chabelskaya, S. & Felden, B. A small RNA controls a protein 
regulator involved in antibiotic resistance in Staphylococcus aureus. Nucleic Acids Res. 
gku149 (2014). doi:10.1093/nar/gku149 
147. Johnson, R. et al. Drug-resistant tuberculosis epidemic in the Western Cape driven by a 
virulent Beijing genotype strain. Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. 
Lung Dis. 14, 119–121 (2010). 
148. Farhat, M. R. et al. Genomic analysis identifies targets of convergent positive selection 
in drug-resistant Mycobacterium tuberculosis. Nat. Genet. 45, 1183–1189 (2013). 
149. Philalay, J. S., Palermo, C. O., Hauge, K. A., Rustad, T. R. & Cangelosi, G. A. Genes 
Required for Intrinsic Multidrug Resistance in Mycobacterium avium. Antimicrob. 
Agents Chemother. 48, 3412–3418 (2004). 
150. Matsunaga, I., Maeda, S., Meda, S., Nakata, N. & Fujiwara, N. The polyketide synthase-
associated multidrug tolerance in Mycobacterium intracellulare clinical isolates. 
Chemotherapy 58, 341–348 (2012). 
151. Takayama, K. & Kilburn, J. O. Inhibition of synthesis of arabinogalactan by ethambutol 
in Mycobacterium smegmatis. Antimicrob. Agents Chemother. 33, 1493–1499 (1989). 
152. Ando, H. et al. Downregulation of katG expression is associated with isoniazid 
resistance in Mycobacterium tuberculosis. Mol. Microbiol. 79, 1615–1628 (2011). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 127 
 
153. Kim, Y. & Wood, T. K. Toxins Hha and CspD and small RNA regulator Hfq are 
involved in persister cell formation through MqsR in Escherichia coli. Biochem. 
Biophys. Res. Commun. 391, 209–213 (2010). 
154. Köten, B. et al. RNase 7 contributes to the cutaneous defense against Enterococcus 
faecium. PloS One 4, e6424 (2009). 
155. Singh, A. & Batra, J. K. Role of unique basic residues in cytotoxic, antibacterial and 
antiparasitic activities of human eosinophil cationic protein. Biol. Chem. 392, 337–346 
(2011). 
156. Pulido, D. et al. Antimicrobial action and cell agglutination by the eosinophil cationic 
protein are modulated by the cell wall lipopolysaccharide structure. Antimicrob. Agents 
Chemother. 56, 2378–2385 (2012). 
157. Boix, E. et al. Structural determinants of the eosinophil cationic protein antimicrobial 
activity. Biol. Chem. 393, 801–815 (2012). 
158. Pulido, D., Torrent, M., Andreu, D., Nogues, M. V. & Boix, E. Two Human Host 
Defense Ribonucleases against Mycobacteria, the Eosinophil Cationic Protein (RNase 
3) and RNase 7. Antimicrob. Agents Chemother. 57, 3797–3805 (2013). 
159. Mraheil, M. A. et al. Comparative genome-wide analysis of small RNAs of major 
Gram-positive pathogens: from identification to application: sRNAs of Gram-positive 
pathogens used as drug targets and for microbial diagnostics. Microb. Biotechnol. 3, 
658–676 (2010). 
160. Kulyté, A., Nekhotiaeva, N., Awasthi, S. K. & Good, L. Inhibition of Mycobacterium 
smegmatis gene expression and growth using antisense peptide nucleic acids. J. Mol. 
Microbiol. Biotechnol. 9, 101–109 (2005). 
161. Park, H., Bak, G., Kim, S. C. & Lee, Y. Exploring sRNA-mediated gene silencing 
mechanisms using artificial small RNAs derived from a natural RNA scaffold in 
Escherichia coli. Nucleic Acids Res. 41, 3787–3804 (2013). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 128 
 
162. Kumar, A., Chandolia, A., Chaudhry, U., Brahmachari, V. & Bose, M. Comparison of 
mammalian cell entry operons of mycobacteria: in silico analysis and expression 
profiling. FEMS Immunol. Med. Microbiol. 43, 185–195 (2005). 
163. WHO | Tuberculosis. WHO | Tuberculosis. WHO (2013). at 
<http://www.who.int/mediacentre/factsheets/fs104/en/> 
164. Pierre-Audigier, C. et al. Fatal disseminated Mycobacterium smegmatis infection in a 
child with inherited interferon gamma receptor deficiency. Clin. Infect. Dis. Off. Publ. 
Infect. Dis. Soc. Am. 24, 982–984 (1997). 
165. Dagert, M. & Ehrlich, S. D. Prolonged incubation in calcium chloride improves the 
competence of Escherichia coli cells. Gene 6, 23–28 (1979). 
166. Ellis, R. C. & Zabrowarny, L. A. Safer staining method for acid fast bacilli. J. Clin. 
Pathol. 46, 559–560 (1993). 
167. Jacobs, W. R., Tuckman, M. & Bloom, B. R. Introduction of foreign DNA into 
mycobacteria using a shuttle phasmid. Nature 327, 532–535 (1987). 
168. Snapper, S. B., Melton, R. E., Mustafa, S., Kieser, T. & Jr, W. R. J. Isolation and 
characterization of efficient plasmid transformation mutants of Mycobacterium 
smegmatis. Mol. Microbiol. 4, 1911–1919 (1990). 
169. Broussard, G. W. Electrocompetent Mycobacterium Cells. Gregory W. Broussard, 
Ph.D. (2009). at <http://gregorybroussard.com/2009/04/21/electrocompetent-
mycobacterium-cells/> 
170. Molecular cloning : a laboratory manual / Joseph Sambrook, David W. Russell. - 
Version details - Trove. at 
<http://trove.nla.gov.au/work/13615226?q&versionId=45739910> 
171. Smabrook, J., Fritsch, E. . & Maniatis, T. Molecular cloning : a laboratory manual (2rd. 
ed). Plain View, N.Y.: Cold Spring Harbor Laboratory Press. (1989). at 
<http://trove.nla.gov.au/work/13615226?q&versionId=45739910> 
Stellenbosch University  https://scholar.sun.ac.za
       Page 129 
 
172. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler 
transform. Bioinforma. Oxf. Engl. 26, 589–595 (2010). 
173. Ponstingl, H. SMALT - Wellcome Trust Sanger Institute. at 
<https://www.sanger.ac.uk/resources/software/smalt/#t_1> 
174. Rozen, S. & Skaletsky, H. Primer3 on the WWW for general users and for biologist 
programmers. Methods Mol. Biol. Clifton NJ 132, 365–386 (2000). 
175. Guo, X. V. et al. Silencing Essential Protein Secretion in Mycobacterium smegmatis by 
Using Tetracycline Repressors. J. Bacteriol. 189, 4614–4623 (2007). 
176. Mirouze, N., Parashar, V., Baker, M. D., Dubnau, D. A. & Neiditch, M. B. An Atypical 
Phr Peptide Regulates the Developmental Switch Protein RapH ▿. J. Bacteriol. 193, 
6197–6206 (2011). 
177. QIAGEN, Germany. QIAGEN - miRNeasy Mini Kit. at 
<http://www.qiagen.com/products/catalog/sample-technologies/rna-sample-
technologies/rna-cleanup/rneasy-minelute-cleanup-kit> 
178. QIAGEN, Germany. QIAGEN - RNeasy MinuElute Kit. at 
<http://www.qiagen.com/products/catalog/sample-technologies/rna-sample-
technologies/total-rna/rneasy-mini-kit#resources> 
179. Koul, A. et al. Delayed bactericidal response of Mycobacterium tuberculosis to 
bedaquiline involves remodelling of bacterial metabolism. Nat. Commun. 5, 3369 
(2014). 
180. QIAGEN, Germany. HotStarTaq DNA Polymerase. at 
<http://www.qiagen.com/products/catalog/assay-technologies/end-point-pcr-and-rt-pcr-
reagents/hotstartaq-dna-polymerase/> 
181. Sirgel, F. A. et al. gyrA mutations and phenotypic susceptibility levels to ofloxacin and 
moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J. Antimicrob. 
Chemother. 67, 1088–1093 (2012). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 130 
 
182. Philalay, J. S., Palermo, C. O., Hauge, K. A., Rustad, T. R. & Cangelosi, G. A. Genes 
required for intrinsic multidrug resistance in Mycobacterium avium. Antimicrob. Agents 
Chemother. 48, 3412–3418 (2004). 
183. Dawson, R. et al. Efficiency and safety of the combination of moxifloxacin, pretomanid 
(PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a 
phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-
resistant pulmonary tuberculosis. The Lancet 385, 1738–1747 (2015). 
184. Raman, S. et al. The Alternative Sigma Factor SigH Regulates Major Components  of 
Oxidative and Heat Stress Responses in  Mycobacterium tuberculosis. J. Bacteriol. 183, 
6119–6125 (2001). 
185. Suzuki, Y. et al. Detection of kanamycin-resistant Mycobacterium tuberculosis by 
identifying mutations in the 16S rRNA gene. J. Clin. Microbiol. 36, 1220–1225 (1998). 
186. Sirgel, F. A. et al. Mutations in the rrs A1401G gene and phenotypic resistance to 
amikacin and capreomycin in Mycobacterium tuberculosis. Microb. Drug Resist. 
Larchmt. N 18, 193–197 (2012). 
187. Marttila, H. J. et al. A Ser315Thr Substitution in KatG Is Predominant in Genetically 
Heterogeneous Multidrug-Resistant Mycobacterium tuberculosis  Isolates Originating 
from the St. Petersburg Area in Russia. Antimicrob. Agents Chemother. 42, 2443–2445 
(1998). 
188. van Soolingen, D. et al. Mutations at amino acid position 315 of the katG gene are 
associated with high-level resistance to isoniazid, other drug resistance, and successful 
transmission of Mycobacterium tuberculosis in the Netherlands. J. Infect. Dis. 182, 
1788–1790 (2000). 
189. Tracevska, T., Jansone, I., Broka, L., Marga, O. & Baumanis, V. Mutations in the rpoB 
and katG Genes Leading to Drug Resistance in Mycobacterium tuberculosis in Latvia. J. 
Clin. Microbiol. 40, 3789–3792 (2002). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 131 
 
190. Yao, C. et al. Detection of rpoB, katG and inhA gene mutations in Mycobacterium 
tuberculosis clinical isolates from Chongqing as determined by microarray. Clin. 
Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 16, 1639–1643 
(2010). 
191. Lew, J. M., Kapopoulou, A., Jones, L. M. & Cole, S. T. TubercuList--10 years after. 
Tuberc. Edinb. Scotl. 91, 1–7 (2011). 
192. Cangelosi, G. A. et al. The Two-Component Regulatory System mtrAB Is Required for 
Morphotypic Multidrug Resistance in Mycobacterium avium. Antimicrob. Agents 
Chemother. 50, 461–468 (2006). 
193. Manske, M. GENtle V1.9.4. (2004). at 
<http://activities.aliexpress.com/bestsellers.php?aff_platform=aaf&sk=zzVR7UnY3%3
A&cpt=1429007454537> 
194. Velayati, A. A. et al. Emergence of New Forms of Totally Drug-Resistant Tuberculosis 
Bacilli Super Extensively Drug-Resistant Tuberculosis or Totally Drug-Resistant Strains 
in Iran. Chest 136, 420–425 (2009). 
195. Udwadia, Z. F., Amale, R. A., Ajbani, K. K. & Rodrigues, C. Totally Drug-Resistant 
Tuberculosis in India. Clin. Infect. Dis. 54, 579–581 (2011). 
196. Kozińska, M. et al. [MDR, pre-XDR and XDR drug-resistant tuberculosis in Poland in 
2000-2009]. Pneumonol. Alergol. Pol. Organ Pol. Tow. Ftyzjopneumonologicznego Pol. 
Tow. Alergol. Inst. Gruźlicy Chorób Płuc 79, 278–287 (2011). 
197. Mudur, G. Indian health ministry challenges report of totally drug resistant tuberculosis. 
BMJ 344, e702 (2012). 
198. Klopper, M. et al. Emergence and Spread of Extensively and Totally Drug-Resistant 
Tuberculosis, South Africa. Emerg. Infect. Dis. 19, 449–455 (2013). 
Stellenbosch University  https://scholar.sun.ac.za
       Page 132 
 
199. Parwati, I., van Crevel, R. & van Soolingen, D. Possible underlying mechanisms for 
successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. 
Lancet Infect. Dis. 10, 103–111 (2010). 
200. Cox, H. S. et al. The Beijing genotype and drug resistant tuberculosis in the Aral Sea 
region of Central Asia. Respir. Res. 6, 134 (2005). 
201. Ghebremichael, S. et al. Drug Resistant Mycobacterium tuberculosis of the Beijing 
Genotype Does Not Spread in Sweden. PLoS ONE 5, e10893 (2010). 
 
 
Stellenbosch University  https://scholar.sun.ac.za
